var title_f29_27_30128="Metastatic choriocarcinoma PA";
var content_f29_27_30128=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Metastatic choriocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A PA chest radiograph demonstrates fuzzy-bordered multiple nodules in a patient with metastatic choriocarcinoma. The indistinct borders are due to local areas of hemorrhage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_27_30128=[""].join("\n");
var outline_f29_27_30128=null;
var title_f29_27_30129="Interactive diabetes case 6: Uncontrolled diabetes in a 64-year-old woman treated with insulin";
var content_f29_27_30129=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interactive diabetes case 6: Uncontrolled diabetes in a 64-year-old woman treated with insulin",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/27/30129/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/27/30129/contributors\">",
"     Lloyd Axelrod, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/27/30129/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/27/30129/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/27/30129/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/27/30129/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/27/30129/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 64-year-old woman, a retired office worker, has persistently variable glucose values on multiple injections of insulin a day.",
"   </p>",
"   <p>",
"    Three years ago the patient was admitted to another hospital in diabetic ketoacidosis in the setting of an upper respiratory infection. She was started on insulin then and has been on insulin ever since, currently taking NPH insulin 20 units every morning and using a sliding scale of aspart insulin sporadically. Her blood glucose values are variable when checked twice a day, before breakfast and before dinner. Most fasting blood glucose values are in the 200 to 300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.1 to 16.7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    range, but some are in the 40 to 60",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.2 to 3.3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    range. Blood glucose values before supper vary from 44 to 327",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.4 to 18.2",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    with no apparent pattern. She is having occasional nocturnal insulin reactions. The hemoglobin A1C is 10.20 percent. The patient says she counts carbohydrates and avoids concentrated sweets. She is 5' 1\" tall, weighs 111 pounds, and has a body mass index (BMI) of 21.",
"   </p>",
"   <p>",
"    What do you recommend?",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 1200 calorie diet to reduce variability in the blood glucose levels. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?29/27/30129-a1?source=see_link\">",
"       \"Interactive diabetes case 6: Uncontrolled diabetes in a 64-year-old woman treated with insulin - A1\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      500 mg po twice a day before meals to reduce the peak glucose values. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?29/27/30129-a2?source=see_link\">",
"       \"Interactive diabetes case 6: Uncontrolled diabetes in a 64-year-old woman treated with insulin - A2\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A sliding scale of aspart insulin at breakfast based on the carbohydrate intake at that time to reduce fluctuations in the blood glucose level later in the day. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?29/27/30129-a3?source=see_link\">",
"       \"Interactive diabetes case 6: Uncontrolled diabetes in a 64-year-old woman treated with insulin - A3\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A redistribution of insulin. You reduce the morning dose of NPH insulin to 10 units before breakfast and add NPH insulin 4 units at bedtime. You also add a dose of aspart insulin before supper, based on the patient's estimated insulin to carbohydrate ratio of one unit for every 25 grams of carbohydrate and correction factor of one unit for every 70",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      of blood glucose above 120",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (6.7",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?29/27/30129-a4?source=see_link\">",
"       \"Interactive diabetes case 6: Uncontrolled diabetes in a 64-year-old woman treated with insulin - A4\"",
"      </a>",
"      .) An approach to estimating the dose of short and very short-acting insulins is discussed separately.&nbsp;(See",
"      <a class=\"medical medical_answer\" href=\"./interactive-diabetes-case-3-hypoglycemia-in-a-patient-with-type-1-diabetes-b2?source=see_link\">",
"       \"Interactive diabetes case 3: Hypoglycemia in a patient with type 1 diabetes - B2\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4173 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.247-661AF214C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_27_30129=[""].join("\n");
var outline_f29_27_30129=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CASE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"./interactive-diabetes-case-3-hypoglycemia-in-a-patient-with-type-1-diabetes-b2?source=related_link\">",
"      Interactive diabetes case 3: Hypoglycemia in a patient with type 1 diabetes - B2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?29/27/30129-a1?source=related_link\">",
"      Interactive diabetes case 6: Uncontrolled diabetes in a 64-year-old woman treated with insulin - A1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?29/27/30129-a2?source=related_link\">",
"      Interactive diabetes case 6: Uncontrolled diabetes in a 64-year-old woman treated with insulin - A2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?29/27/30129-a3?source=related_link\">",
"      Interactive diabetes case 6: Uncontrolled diabetes in a 64-year-old woman treated with insulin - A3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?29/27/30129-a4?source=related_link\">",
"      Interactive diabetes case 6: Uncontrolled diabetes in a 64-year-old woman treated with insulin - A4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_27_30130="Abdominal wall hernias";
var content_f29_27_30130=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F52358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F52358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    Abdominal wall hernias",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 480px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Congenital umbilical hernia. B) Infantile umbilical hernia. C) Paraumbilical hernia. D) Epigastric hernia. E) Separation of recti abdominis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Snell, RS. Clinical Anatomy By Regions, Eighth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_27_30130=[""].join("\n");
var outline_f29_27_30130=null;
var title_f29_27_30131="Nitrous oxide: Patient drug information";
var content_f29_27_30131=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nitrous oxide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"     see \"Nitrous oxide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to put you to sleep for surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702614",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nitrous oxide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hallucinations.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698973",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694896",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For breathing in only.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12089 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-125.69.132.100-32DA4B247A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_27_30131=[""].join("\n");
var outline_f29_27_30131=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013472\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013471\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013475\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013476\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013478\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013474\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013480\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=related_link\">",
"      Nitrous oxide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_27_30132="Brugia timori smear";
var content_f29_27_30132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Brugia timori smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 231px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A, B) Microfilariae of",
"    <em>",
"     B. timori",
"    </em>",
"    in a thick blood smear from a patient from Indonesia, stained with Giemsa and captured at 500x oil magnification. The organism has a sheath (yellow arrow) and two nuclei in its tail (red arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Filariasis. Available at:",
"     <a href=\"file://dpd.cdc.gov/dpdx/html/Filariasis.htm\" target=\"_blank\">",
"      file://dpd.cdc.gov/dpdx/html/Filariasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_27_30132=[""].join("\n");
var outline_f29_27_30132=null;
var title_f29_27_30133="Adefovir: Patient drug information";
var content_f29_27_30133=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Adefovir: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     see \"Adefovir: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/34/10789?source=see_link\">",
"     see \"Adefovir: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F130623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hepsera&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4663221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hepsera&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hepatitis may get worse if this drug is stopped. Close watching is needed when therapy is stopped. HIV testing may be offered. Any HIV infection may be hard to treat after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems and a change in acid levels in the blood. Closely read the part in this leaflet which lists when to call your doctor. Pregnancy, obesity, and/or longer therapy may raise this chance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700776",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause kidney function to get worse. Talk with your doctor if you have kidney disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hepatitis B infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701442",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to adefovir or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696711",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not breast-feed if you have HIV disease unless your doctor tells you to.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698656",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling cold.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose, brand, or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11275 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-6A22C7A760-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_27_30133=[""].join("\n");
var outline_f29_27_30133=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130623\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4663221\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026739\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026741\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026740\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026745\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026746\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026748\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026743\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026744\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026749\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026750\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=related_link\">",
"      Adefovir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/34/10789?source=related_link\">",
"      Adefovir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_27_30134="Potassium iodide: Drug information";
var content_f29_27_30134=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Potassium iodide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/38/23141?source=see_link\">",
"    see \"Potassium iodide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/28/36293?source=see_link\">",
"    see \"Potassium iodide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      iOSAT&trade; [OTC];",
"     </li>",
"     <li>",
"      SSKI&reg;;",
"     </li>",
"     <li>",
"      ThyroSafe&reg; [OTC];",
"     </li>",
"     <li>",
"      Thyroshield&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F212014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote;",
"     </li>",
"     <li>",
"      Antithyroid Agent;",
"     </li>",
"     <li>",
"      Expectorant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F211987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      RDA:",
"     </b>",
"     150 mcg (iodine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Expectorant (SSKI&reg;):",
"     </b>",
"     Oral: 300-600 mg (0.3-0.6 mL) 3-4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Thyroid block following nuclear radiation emergency (iOSAT&trade;, ThyroSafe&reg;, ThyroShield&reg;): Includes pregnant/lactating women:",
"     </b>",
"     Oral: 130 mg once daily, continue for 10-14 days or as directed by public officials (until risk of exposure has passed or other measures are implemented)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Thyroidectomy preparation (unlabeled use):",
"     </b>",
"     Oral: 50-100 mg (1-2 drops",
"     <b>",
"      or",
"     </b>",
"     0.05-0.1 mL SSKI&reg;) 3 times daily; administer for 10 days before surgery; if not euthyroid prior to surgery, consider concurrent beta-blockade (eg, propranolol) in the immediate preoperative period to reduce the risk of thyroid storm (Bahn, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sporotrichosis (cutaneous, lymphocutaneous; unlabeled use) (SSKI&reg;):",
"     </b>",
"     Oral: Initial: 5 drops 3 times daily; increase to 40-50 drops 3 times daily as tolerated until 2-4 weeks after lesions have resolved (usual duration 3-6 months) (Kauffman, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Thyroid gland protection during radiopharmaceutical use (unlabeled use):",
"     </b>",
"     Oral: Tablet: 130 mg once daily",
"     <b>",
"      or",
"     </b>",
"     Solution (SSKI&reg;): 4 drops 3 times daily (Bexxar&reg; prescribing information, 2012).",
"     <b>",
"      Note:",
"     </b>",
"     Begin at 1-48 hours prior to exposure. Continue potassium iodide after radiopharmaceutical administration until risk of exposure has diminished (treatment duration and time of initiation is dependent on the radiopharmaceutical, consult specific protocol).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Thyrotoxic crisis/thyroid storm (unlabeled use):",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Administer at least 1-2 hours after antithyroid drug administration: 250 mg (5 drops",
"     <b>",
"      or",
"     </b>",
"     0.25 mL SSKI&reg;) every 6 hours (Bahn, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F212001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/28/36293?source=see_link\">",
"      see \"Potassium iodide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Thyroid block following nuclear radiation emergency (iOSAT&trade;, ThyroSafe&reg;, ThyroShield&reg;):",
"     </b>",
"     Dosing should continue for 10-14 days or as directed by public officials (until risk of exposure has passed or other measures are implemented): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &le;1 month: 16.25 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &gt;1 month to Children &le;3 years: 32.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;3 to &le;12 years: 65 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12-18 years weighing &lt;68 kg: 65 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12-18 years weighing &ge;68 kg: 130 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Thyroidectomy preparation (unlabeled use):",
"     </b>",
"     Oral: 150-350 mg (3-7 drops",
"     <b>",
"      or",
"     </b>",
"     0.15-0.35 mL SSKI&reg;) 3 times daily; administer for 10 days before surgery; if not euthyroid prior to surgery, consider concurrent beta-blockade (eg, propranolol) in the immediate preoperative period to reduce the risk of thyroid storm (Bahn, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Thyroid gland protection during radiopharmaceutical use (unlabeled use):",
"     </b>",
"     Oral (Giammarile, 2008; Olivier, 2003):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &lt;5 kg: 16 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1 month to 3 years or 5-15 kg: 32 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 3-13 years or 15-50 kg: 65 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;13 years or &gt;50 kg: 130 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Begin at 1-48 hours prior to exposure. Continue potassium iodide after radiopharmaceutical administration until risk of exposure has diminished (treatment duration and time of initiation is dependent on the radiopharmaceutical, consult specific protocol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Thyrotoxic crisis/thyroid storm (unlabeled use):",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Administer at least 1-2 hours after antithyroid drug administration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 100 mg (2 drops",
"     <b>",
"      or",
"     </b>",
"     0.1 mL SSKI&reg;) 4 times daily (Eyal, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 250 mg (5 drops",
"     <b>",
"      or",
"     </b>",
"     0.25 mL SSKI&reg;) 2-4 times daily (Eyal, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F211988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16562921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16562922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SSKI&reg;: 1 g/mL (30 mL, 237 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thyroshield&reg;: 65 mg/mL (30 mL) [contains propylene glycol; black raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     iOSAT&trade;: 130 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ThyroSafe&reg;: 65 mg [scored; equivalent to iodine 50 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13755335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F211965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     SSKI&reg;: Dilute in a glassful of water, fruit juice, or milk. Take with food or milk to decrease gastric irritation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     iOSAT&trade;, Thyrosafe&reg;, Thyroshield&reg;: Take as soon as possible after instructed to do so by public officials. Take every 24 hours; do not take more than 1 dose in 24 hours. Tablets may be crushed and mixed with water, low fat milk (white or chocolate), orange juice, soda (flat), raspberry syrup, or infant formula.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F211964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Expectorant for the symptomatic treatment of chronic pulmonary diseases complicated by mucous; block thyroidal uptake of radioactive isotopes of iodine in a nuclear radiation emergency",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F212011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lymphocutaneous and cutaneous sporotrichosis; reduce thyroid vascularity prior to thyroidectomy; management of thyrotoxic crisis; block thyroidal uptake of radioactive isotopes of iodine after therapeutic or diagnostic exposure to radioactive iodine",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F802361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Potassium iodide products, including saturated solution of potassium iodide (SSKI&reg;) may be confused with potassium iodide and iodine (Strong Iodide Solution or Lugol's solution)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F212012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrhythmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, fatigue, fever, numbness, tingling sensation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Skin rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Goiter, hyperthyroidism (prolonged use), hypothyroidism (prolonged use), myxedema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, enlargement of salivary glands, gastric distress, gastrointestinal hemorrhage, metallic taste, nausea, stomach pain, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic &amp; oncologic: Lymphedema, thyroid adenoma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hypersensitivity: Hypersensitivity reaction (angioedema, cutaneous and mucosal hemorrhage, serum sickness-like symptoms)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Musculoskeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Iodine poisoning (with prolonged treatment/high doses)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F211969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to iodide, iodine, or any component of the formulation; dermatitis herpetiformis; hypocomplementemic vasculitis, nodular thyroid condition with heart disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F211951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Iodide hypersensitivity may occur, manifesting as angioedema, cutaneous/mucosal hemorrhage, and serum sickness-like symptoms (fever, arthralgia, lymph node enlargement, and eosinophilia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: Can cause acne flare-ups and/or dermatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid adverse effects: Prolonged use may lead to hypothyroidism. Iodide may cause underactive or overactive thyroid; thyroid enlargement may also occur. Use with caution in patients with a history of hyperthyroidism; use is contraindicated in patients with nodular thyroid condition (goiter) with heart disease. Iodism or chronic iodide poisoning may occur with high doses or prolonged treatment; symptoms include burning of mouth/throat, sore teeth/gums, severe headache, metallic taste, eye irritation/eye lid swelling, increased salivation, acneform skin lesions, and (rarely) severe skin lesions;  withhold potassium iodide treatment and manage with supportive care.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchitis: Use with caution in patients with acute bronchitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac disease: Use with caution in patients with cardiac disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myotonia congenita: Use with caution in patients with myotonia congenita.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tuberculosis: Use with caution in patients with tuberculosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: In a nuclear radiation emergency, infants and children are more likely to experience thyroid damage.  Infants &lt;1 month are at higher risk for hypothyroidism with potassium iodide use; evaluate thyroid function if repeat dosing is required in this patient population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For thyroid gland protection (radiopharmaceutical use), potassium iodide must be administered prior to receiving radiopharmaceuticals that require thyroid gland protection. For nuclear radiation emergency, take only when instructed by public health officials; do not take more or more often than instructed; follow other emergency measures recommended by officials.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F211956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium Salts may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antithyroid Agents may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Potassium Iodide may enhance the hypothyroid effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Iodide I131: Antithyroid Agents may diminish the therapeutic effect of Sodium Iodide I131.  Management: Discontinue antithyroid therapy 3-4 days prior to sodium iodide I-131 administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Antithyroid Agents may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antithyroid Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F211959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F211973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iodide crosses the placenta (may cause hypothyroidism and goiter in fetus/newborn). Use as an expectorant during pregnancy is contraindicated by the AAP. Use for protection against thyroid cancer secondary to radioactive iodine exposure is considered acceptable based upon risk:benefit, keeping in mind the dose and duration. In general, medications used as as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2003). Pregnant women should take as instructed by public officials and contact their physician. Repeat dosing should be avoided if possible. Refer to Iodine monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F211992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F211974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potassium iodide is excreted in breast milk. AAP considers this drug compatible, but recommends avoiding breast-feeding following radioactive iodine exposure unless no alternative is available. May cause skin rash in nursing infant. Nursing mothers should take as instructed by public officials and contact their physician. Refer to Iodine monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F211975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SSKI&reg;: Take with food  or milk to decrease gastric irritation.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F211972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (SSKI Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g/mL (30 mL): $20.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (ThyroShield Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     65 mg/mL (30 mL): $15.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Iosat Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     130 mg (14): $10.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Potassium Iodide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     32.5 (24 I) mg (100): $3.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (ThyroSafe Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     65 mg (20): $7.36",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F211961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Thyroid function tests, signs/symptoms of hyperthyroidism; thyroid function should be monitored in pregnant or breast-feeding women, neonates, and young infants if repeat doses are required following radioactive iodine exposure",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cato-Bell (IN);",
"     </li>",
"     <li>",
"      Iodid (BE);",
"     </li>",
"     <li>",
"      Iodure de Potassium (FR);",
"     </li>",
"     <li>",
"      Ioduro Potasico Rovi (ES);",
"     </li>",
"     <li>",
"      Jodam (PL);",
"     </li>",
"     <li>",
"      Jodetten Henning (DE);",
"     </li>",
"     <li>",
"      Jodgamma (DE);",
"     </li>",
"     <li>",
"      Jodid (DE, HU, LU, PL);",
"     </li>",
"     <li>",
"      Jodid Merck (AT);",
"     </li>",
"     <li>",
"      Jodid Verla (DE);",
"     </li>",
"     <li>",
"      Jodid-ratiopharm (DE);",
"     </li>",
"     <li>",
"      Jodix (FI);",
"     </li>",
"     <li>",
"      Jodostin (PL);",
"     </li>",
"     <li>",
"      Jodox (PL);",
"     </li>",
"     <li>",
"      Kalium jodatum (DE);",
"     </li>",
"     <li>",
"      Kaliumiodid (CH);",
"     </li>",
"     <li>",
"      Kaliumiodid BC (DE);",
"     </li>",
"     <li>",
"      Kaliumjodid Lannacher (AT);",
"     </li>",
"     <li>",
"      Kaliumjodid Recip (SE);",
"     </li>",
"     <li>",
"      Kaliumjodid &rdquo;Dak&rdquo; (DK);",
"     </li>",
"     <li>",
"      Mono-Jod (DE);",
"     </li>",
"     <li>",
"      Tarjod (PL);",
"     </li>",
"     <li>",
"      Thyroprotect (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F211950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduces viscosity of mucus by increasing respiratory tract secretions; inhibits secretion of thyroid hormone, fosters colloid accumulation in thyroid follicles. Following radioactive iodine exposure, potassium iodide blocks the uptake of radioactive iodine by the thyroid, reducing the risk of thyroid cancer.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F211968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Hyperthyroidism: 24-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 10-15 days after continuous therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Radioactive iodine exposure: Each dose has a duration of ~24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      \"Adverse Reactions to Iodide Therapy of Asthma and Other Pulmonary Diseases,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1976, 57(2):272-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/27/30134/abstract-text/1250663/pubmed\" id=\"1250663\" target=\"_blank\">",
"        1250663",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/27/30134/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;American Academy of Pediatrics Committee on Environmental Health. Radiation Disasters and Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2003, 111(6 Pt 1):1455-66.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bahn RS (Chair), Burch HB, Cooper DS, et al, &ldquo;Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists,&rdquo;",
"      <i>",
"       Thyroid",
"      </i>",
"      , 2011, 21(6):593-646.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/27/30134/abstract-text/ 21510801/pubmed\" id=\" 21510801\" target=\"_blank\">",
"        21510801",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bailey B, \"Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?\"",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(2):133-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/27/30134/abstract-text/12769509/pubmed\" id=\"12769509\" target=\"_blank\">",
"        12769509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eyal O and Rose SR, &ldquo;Thyroid Disease,&rdquo; in",
"      <i>",
"       Roger&rsquo;s Textbook of Pediatric Intensive Care",
"      </i>",
"      , 4th ed, David G Nichols, ed, Philadelphia, PA: Lippincott, Williams, &amp; Wilkins, 2008.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giammarile F, Chiti A, Lassmann M, et al, &ldquo;EANM Procedure Guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) Therapy,&rdquo;",
"      <i>",
"       Eur J Nucl Med Mol Imaging",
"      </i>",
"      , 2008, 35(5):1039-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/27/30134/abstract-text/18274745/pubmed\" id=\"18274745\" target=\"_blank\">",
"        18274745",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hassoun A and Oberfield SE, &ldquo;Renal, Endocrine, and Metabolic Disorders,&rdquo; in",
"      <i>",
"       Roger&rsquo;s Textbook of Pediatric Intensive Care",
"      </i>",
"      , 3rd ed, David G Nichols, ed, Philadelphia, PA: Lippincott, Williams, &amp; Wilkins, 2008; p.1658.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kauffman CA, Bustamante B, Chapman SW, et al, &ldquo;Clinical Practice Guidelines for the Management of Sporotrichosis: 2007 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2007, 45(10):1255-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/27/30134/abstract-text/17968818/pubmed\" id=\"17968818\" target=\"_blank\">",
"        17968818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kauffman CA, Hajjeh R, and Chapman SW, &ldquo;Practice Guidelines for the Management of Patients With Sporotrichosis. For the Mycoses Study Group. Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2000, 30(4):684-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nayak B and Burman K, &ldquo;Thyrotoxicosis and Thyroid Storm,&rdquo;",
"      <i>",
"       Endocrinol Metab Clin North Am",
"      </i>",
"      , 2006,35(4):663-86, vii.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/27/30134/abstract-text/17127140/pubmed\" id=\"17127140\" target=\"_blank\">",
"        17127140",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olivier P, Colarinha P, Fettich J, et al, &ldquo;Guideline for Radioiodinated MIBG Scintigraphy in Children,&rdquo;",
"      <i>",
"       Eur J Nucl Med Mol Imaging",
"      </i>",
"      , 2003, 30(5):B45-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/27/30134/abstract-text/12658506/pubmed\" id=\"12658506\" target=\"_blank\">",
"        12658506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Potassium Iodide as a Thyroid Blocking Agent in a Radiation Emergency: Final Recommendations on Use,&rdquo; Washington DC, Bureau of Radiological Health and Bureau of Drugs, Food and Drug Administration, 1982.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Food and Drug Administration, &ldquo;FDA's Guidance on Protection of Children and Adults Against Thyroid Cancer in Case of Nuclear Accident,&rdquo; FDA Talk Paper. Available at",
"      <a href=\"file://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm133711.htm\" target=\"_blank\">",
"       file://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm133711.htm",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9798 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-76D4E16EBB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_27_30134=[""].join("\n");
var outline_f29_27_30134=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211985\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212014\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211987\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212001\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211988\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16562921\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16562922\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211963\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13755335\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211965\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211964\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212011\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F802361\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212012\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211969\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211951\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299922\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211956\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211959\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211973\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211992\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211974\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211975\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211972\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211961\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038775\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211950\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211968\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9798\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9798|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/38/23141?source=related_link\">",
"      Potassium iodide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/28/36293?source=related_link\">",
"      Potassium iodide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_27_30135="Endotheliitis liver TPL";
var content_f29_27_30135=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endotheliitis in acute hepatic allograft rejection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a liver biopsy from a liver transplant shows endotheliitis involving a central hepatic vein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Donald Jensen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_27_30135=[""].join("\n");
var outline_f29_27_30135=null;
var title_f29_27_30136="Sunburn";
var content_f29_27_30136=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sunburn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/27/30136/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/27/30136/contributors\">",
"     Sylvia Brice, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/27/30136/contributors\">",
"     Kathryn R Shrift, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/27/30136/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/27/30136/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/27/30136/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/27/30136/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/27/30136/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/27/30136/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 9, 2009.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The painful, erythematous reaction of the skin in response to excessive sun exposure known as sunburn is a well-known and commonly experienced phenomenon. In the United States, 30 to 40 percent of adults and 70 to 85 percent of children and adolescents have reported at least one sunburn in the previous year [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Sunburn's importance derives not only from the acute discomfort it causes, but also because it is a marker for excess sun exposure and, therefore, skin cancer, especially basal cell carcinoma and melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=see_link\">",
"     \"Epidemiology and clinical features of basal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link\">",
"     \"Risk factors for the development of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Excessive sun exposure can occasionally cause more severe burns, and these are managed similarly to other burns. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37479?source=see_link\">",
"     \"Treatment of minor thermal burns\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of the sunburn response has not been fully elucidated. Multiple pathways are thought to be involved.",
"   </p>",
"   <p>",
"    At a molecular level, exposure to ultraviolet (UV) irradiation, particularly ultraviolet B (UVB) light with a wavelength between 290 and 320 nm, is known to induce DNA mutagenesis, especially the formation of cyclobutane pyrimidine dimers and pyrimidine (6-4) photoproducts [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/10\">",
"     10",
"    </a>",
"    ]. Subsequent induction of the p53 pathway then leads to either growth arrest and DNA repair or programmed cell death [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/10\">",
"     10",
"    </a>",
"    ]. Apoptosis serves a likely protective role by eliminating cells with damaged DNA and resultant malignant potential, and it is mediated by several mechanisms including induction of nuclear DNA damage, activation of membrane-bound cell death receptors, and generation of reactive oxygen species [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histologically, dyskeratotic cells in the upper stratum spinosum known as sunburn cells (SBCs) are characteristically seen within 24 hours after UV exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/12\">",
"     12",
"    </a>",
"    ]. The number of SBCs appears to be dose-related and is highly correlated with apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Acute UV exposure may also deplete Langerhans cells, the skin's antigen-presenting cells, and induce thickening of the stratum corneum, epidermis and dermis, dermal edema, and perivascular neutrophilic infiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/10,12,13\">",
"     10,12,13",
"    </a>",
"    ]. Dermal vasodilatation is thought to be largely responsible for the skin's visible erythema [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SUSCEPTIBILITY AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exposure to UV radiation required to produce sunburn is variable among individuals. Increased susceptibility can be expected in individuals with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fair skin",
"     </li>",
"     <li>",
"      Light-colored hair",
"     </li>",
"     <li>",
"      History of sunburn with limited exposures to sunlight",
"     </li>",
"     <li>",
"      Use of photosensitizing medications: NSAIDs, quinolones, tetracyclines, psoralens, thiazides, furosemide,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , and the phenothiazines are relatively common causes of photosensitivity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Fitzpatrick skin phototype is a classification of skin type based on risk for sunburn (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As mentioned above, in the United States, 30 to 40 percent of adults and 70 to 85 percent of children and adolescents have reported at least one sunburn in the previous year [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. As an example, in a survey of more than 200,000 adults in the United States, 39 percent reported at least one sunburn in the prior 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/4\">",
"     4",
"    </a>",
"    ]. Sunburn was most common in individuals ages 18 to 24 (61 percent). Excessive alcohol consumption is associated with an increased risk of sunburn [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/4,15\">",
"     4,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES AND DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     General issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individual response to UV exposure is highly variable depending on skin type, chronicity of exposure, and genetic determinants.",
"   </p>",
"   <p>",
"    Clinical cutaneous manifestations of sunburn range from painless erythema to highly painful erythema with edema and blistering in sun-exposed areas (",
"    <a class=\"graphic graphic_picture graphicRef73224 graphicRef52112 \" href=\"UTD.htm?12/19/12599\">",
"     picture 1A-B",
"    </a>",
"    ). In general, erythema is first noted at approximately three to five hours following UVB exposure, peaks at between 12 to 24 hours, and fades over 72 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnosis is usually not difficult based on symptomatology and a recent history of sun exposure. The appearance of a characteristic reaction on sun-exposed skin with sparing of skin that was covered or shaded is usually sufficient to diagnose sunburn.",
"   </p>",
"   <p>",
"    The diagnosis may occasionally be more difficult with unusual patterns of sunburn in patients who do not recognize the exposure. As an example, car drivers or passengers on long trips may get sunburn on just one surface of an arm that was rested out an open window.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for sunburn includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polymorphous light eruption &mdash; This is a sunlight-induced photodistributed eruption characterized by erythematous papules, vesicles, and plaques in a patchy, usually symmetrical distribution. It is generally pruritic and may be a chronic, recurring, or short-lived problem. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29831?source=see_link&amp;anchor=H8#H8\">",
"       \"Approach to the patient with macular skin lesions\", section on 'Polymorphous light eruption'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Solar urticaria &mdash; This photodistributed reaction to sunlight is characterized by transient wheals or, less commonly, erythema alone and generally occurs after only minutes of sun exposure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=see_link\">",
"       \"New onset urticaria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Systemic lupus erythematosus &mdash; Symptoms of this autoimmune, multisystem disease may include photosensitivity, most frequently presenting as the so-called \"butterfly rash\" with erythema in a malar distribution. Cutaneous symptoms may precede involvement of other organ systems. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=see_link\">",
"       \"Overview of the clinical manifestations of systemic lupus erythematosus in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Xeroderma pigmentosum &mdash; This autosomal recessive defect in DNA nucleotide excision repair may present with sunburn in a young child after minimal sun exposure. Patients often develop squamous cell carcinomas, basal cell carcinomas, and melanoma in childhood. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H16#H16\">",
"       \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'Xeroderma pigmentosum'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Erythropoietic protoporphyria &mdash; This uncommon autosomal dominant disorder may present in infancy or early childhood with severe photosensitivity including erythema with papules, vesicles, and urticaria-like plaques in response to minimal sun exposure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15834?source=see_link\">",
"       \"Erythropoietic protoporphyria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug-induced photosensitivity &mdash; Exaggerated sunburn reactions may result from the combination of UV exposure and the use of photosensitizing agents. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Susceptibility and epidemiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link&amp;anchor=H12#H12\">",
"       \"Drug eruptions\", section on 'Photosensitivity'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention is the key to managing sunburn, and several means of sun protection ought to be employed to avoid cutaneous UV damage. A number of routine, highly effective sun avoidance measures should be recommended to all patients, especially those with increased susceptibility to sunburn. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Susceptibility and epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sun protection factor (SPF)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sun protection factor (SPF) is a measure of the ability of an intervention (typically clothing or sunscreen) to prevent erythema in response to sun exposure. The SPF can be multiplied by the time of exposure necessary to produce minimal erythema in an unprotected individual to get the expected time until minimal erythema using that protection. As an example, if an unprotected individual develops minimal erythema after 20 minutes of sun exposure, after use of an SPF-15 sunscreen, minimal erythema would be expected after 300 minutes (5 hours) of exposure. As discussed below, however, the duration of protection with sunscreen may be shorter in many circumstances than the SPF would indicate (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Sunscreen'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Avoid UV exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals should be advised to seek shade, especially during summer months between the hours of 10:00 AM and 4:00 PM. Patients should be informed that cloudy days do not provide an occasion to skip such measures, as sufficient UVB may pass through the clouds to cause significant sunburn. Indoor UV tanning beds may also cause sunburn, even though they primarily emit UVA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/16\">",
"     16",
"    </a>",
"    ]. Tanning beds should be avoided (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Tanning'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clothing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wide-brimmed hats, sunglasses, and loose-fitting clothing with long sleeves and pants will provide protection from harmful UV rays [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/17\">",
"     17",
"    </a>",
"    ]. Clothing made from tighter-woven, darker fabrics tend to provide greater protection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/18\">",
"     18",
"    </a>",
"    ]. Some manufacturers have begun producing sun-protective clothing with a minimum SPF as well as UV absorbing agents that may be applied to clothing during laundering [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sunscreen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sunscreen constitutes the mainstay of sunburn prevention, protecting the skin by absorbing or reflecting UV radiation. For purposes of avoiding sunburn, the SPF, which specifically reflects ability to prevent erythema, is of greatest importance in choosing a sunscreen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/20\">",
"     20",
"    </a>",
"    ]. It is important to note, however, that while SPF may correlate well with degree of protection against UVB [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/21\">",
"     21",
"    </a>",
"    ], it does not ensure adequate protection against UVA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. Chronic UVA exposure is thought to play a key role in photoaging [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sunscreens are frequently classified as either",
"    <span class=\"nowrap\">",
"     physical/inorganic",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     chemical/organic",
"    </span>",
"    sunscreens (",
"    <a class=\"graphic graphic_table graphicRef73127 \" href=\"UTD.htm?6/27/6589\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical sunscreens contain large particulate substances such as titanium dioxide, zinc oxide, talc, kaolin, ferric chloride, ichthammol (Ichthyol), and various colored clays, which act to reflect and scatter both visible and UV light [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/28\">",
"       28",
"      </a>",
"      ]. While these sunscreens protect from a broad spectrum of light, aesthetically unappealing qualities characteristic of many of these products, including opaqueness, tendency to stain clothing, and comedogenesis, may lead to insufficient application and resultant decreased effectiveness [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chemical sunscreens absorb rather than reflect UV radiation, and they typically have a limited spectrum of protection. In the past, chemical sunscreens have acted primarily to absorb only erythrogenic UVB radiation; para-aminobenzoic acid (PABA), PABA esters, salicylates, camphor derivatives, and cinnamates are in this category [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/20,28\">",
"       20,28",
"      </a>",
"      ]. More recently, increasing attention on the importance of protecting against UVA exposure has lead to the development of chemical sunscreens acting to absorb these wavelengths as well; these include dibenzoylmethanes, anthranilates, benzophenones, triazoles, and some camphor derivatives [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/20,28\">",
"       20,28",
"      </a>",
"      ]. Ideal sunscreen products protect against UVB and UVA and may accomplish this by using a combination of agents [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/30\">",
"       30",
"      </a>",
"      ]. As an example, a study that compared pigmentation response to experimental UVA exposure in 12 volunteers treated with six different commercially-produced sunscreens with an SPF of at least 20 found that a preparation containing ecamsule (Mexoryl SX) 3.3 percent, 4-Methylbenzylidene camphor 5 percent, avobenzone (Parsol 1789) 3.5 percent, and titanium dioxide 4.1 percent provided significantly better protection than other preparations [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Proper application of sunscreen is essential to achieving full benefit from a given SPF. Sunscreens should be uniformly applied approximately 15 to 30 minutes before sun exposure. The American Academy of Dermatology recommends a sunscreen of SPF 30 or higher be used in most circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Internationally agreed-upon standards provide for the determination of a sunscreen's SPF when tested at a thickness of 2",
"    <span class=\"nowrap\">",
"     mg/cm2",
"    </span>",
"    (approximately 30 to 35",
"    <span class=\"nowrap\">",
"     mL/",
"    </span>",
"    body application). However, individuals likely apply significantly less than this in practice, which may lead to an effectively lower level of protection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/20,32-34\">",
"     20,32-34",
"    </a>",
"    ]. Effective SPF may decrease exponentially with decreasing sunscreen quantity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Appropriate reapplication is also important and can significantly reduce risk of sunburn [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/36\">",
"     36",
"    </a>",
"    ]. While reapplication every two to three hours has traditionally been recommended, some evidence suggests that reapplication as soon as 20 minutes after initiation of UV exposure, largely to compensate for inadequate initial application, may offer greater protection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/37\">",
"     37",
"    </a>",
"    ]. Sunscreens that are not water-resistant or waterproof are typically less adherent to the skin and require more frequent application [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some trials have found that individuals may choose to spend more time in the sun when using sunscreen for protection or when using higher SPF sunscreen, and this increased duration of exposure may lead to less beneficial effects on total UV exposure than would otherwise be expected from the use of sunscreen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. However, at least one trial did not find this result and found lower rates of sunburn in vacationers given higher SPF sunscreen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemical sunscreens may degrade over time and exposure to high temperatures (eg, car, beach) may speed the process. Sunscreen manufacturers and others recommend not using sunscreen that has passed the expiration date listed on the bottle [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/41\">",
"     41",
"    </a>",
"    ]; for sunscreen that does not have an expiration date, a typical recommendation is to dispose of sunscreen after three years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     In children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The measures to prevent sunburn that are described above can be used in children as well as adults. The safety of sunscreen in children under the age of six months has not been evaluated. For infants younger than six months, the American Academy of Pediatrics recommends avoidance of sun exposure and the use of clothing (eg, lightweight pants, long-sleeved shirts, brimmed hats) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/42\">",
"     42",
"    </a>",
"    ]. A minimal amount of sunscreen with an SPF of &ge;15 may be applied to small areas (eg, face, back of hands) when adequate clothing and shade are not available.",
"   </p>",
"   <p>",
"    Compliance with sun protective practices is inadequate in the adolescent population. In a survey of 10,079 youth (ages 12 to 18) in the United States, 83 percent reported at least one sunburn during the summer, and 34 percent reported three or more sunburns [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/2\">",
"     2",
"    </a>",
"    ]. In a subsequent Australian study, adolescents were more likely to sunburn and were less likely to engage in sun protective practices than adults [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By engaging in sunscreen use and encouraging sunscreen use in their adolescent children, parents may increase the likelihood that their adolescents participate in protective behavior. In one survey, adolescent children of parents who used sunscreen frequently were 30 percent more likely to use sunscreen frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Antioxidants",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have found evidence that oral or topical antioxidants (eg, vitamins A, C, and E, and green tea polyphenols) provide some protection against sunburn [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/45-55\">",
"     45-55",
"    </a>",
"    ]. Insufficient evidence exists to support their use in place of traditional sunscreens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Tanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is little evidence from controlled trials, in individuals with skin complexions that tan, gradual sun exposure that allows tanning appears to decrease the risk of sunburn [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/56\">",
"     56",
"    </a>",
"    ]. However, it is believed that any benefit that may be incurred in preventing acute sunburn is unlikely to extend to prevention of long-term consequences of sun exposure such as skin cancer and photoaging. Experimental evidence suggests that tanned skin is more susceptible to photodamage than the skin of individuals who are more darkly pigmented at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/57\">",
"     57",
"    </a>",
"    ]. As such, gradual tanning in the sun is not felt to be a safe method for preventing sunburn.",
"   </p>",
"   <p>",
"    The efficacy of tanning beds in preventing sunburn is less clear. Tanning beds either use UVA or combined UVA and UVB. Some studies of UVA-induced tanning do suggest effectiveness in protecting against sunburn [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/56,58,59\">",
"     56,58,59",
"    </a>",
"    ]; however, evidence is limited and conflicting. In addition, both UVA and combined",
"    <span class=\"nowrap\">",
"     UVA/UVB",
"    </span>",
"    tanning beds can produce sunburns [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The World Health Organization International Agency for Research on Cancer classified ultraviolet light emitted from tanning devices as a human carcinogen, based upon evidence from several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/61\">",
"     61",
"    </a>",
"    ]. A comprehensive meta-analysis of observational studies found a 75 percent increase in the risk of cutaneous melanoma in individuals who utilized tanning devices before the age of 35 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/62\">",
"     62",
"    </a>",
"    ]. In addition, case control studies have supported an association between tanning devices and ocular melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some individuals utilize tanning devices to tan their skin prior to a period of intense sun exposure, such as travel to a sunny location, as a preventive measure against sunburn. Due to the carcinogenic potential of ultraviolet light, tanning beds should not be used for this purpose.",
"   </p>",
"   <p>",
"    For those who desire a \"tanned\" appearance, topical tanning lotions or sprays offer an alternative to ultraviolet exposure. These products contain dihydroxyacetone (DHA), a chemical that reacts with amino acids in the stratum corneum forming a brown complex that stains the skin. DHA products provide only a minimal amount of protection from ultraviolet light (a maximum SPF of 3 that decreases over time), and may accelerate the production of UV-induced free radicals in the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Thus, DHA should not be used for sun protection. Sunless tanning products that stimulate cutaneous melanogenesis are under development [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/67\">",
"     67",
"    </a>",
"    ]. These may provide more precise mimicry of UV-induced tans, and could offer a UV protective effect [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of treatments aimed at altering the course of sunburn have been explored. While there have been some favorable results, these have not been sufficiently reproducible or of sufficient clinical benefit to warrant recommending these treatments for the purpose of hastening recovery or reversing injury [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/70\">",
"     70",
"    </a>",
"    ]. Use of some of these same therapies for symptomatic relief, however, may be of benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both topical and oral NSAIDs have been studied in the treatment of sunburn and appear to decrease erythema if applied before or immediately after exposure to UVB [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/70\">",
"     70",
"    </a>",
"    ]. The beneficial effect generally decreases past 24 hours.",
"   </p>",
"   <p>",
"    A randomized trial of topical diclofenac 0.1 percent gel in 172 healthy subjects with Fitzpatrick phototype II-IV skin (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"     table 1",
"    </a>",
"    ) did show benefits for a longer period after the time of exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/71\">",
"     71",
"    </a>",
"    ]. Subjects were exposed to sunlight on 15 percent of the body surface area at 2.8 times their individual minimal erythema dose and were then treated with diclofenac gel or placebo vehicle at 6 and 10 hours after exposure. Pain and erythema were significantly decreased during the 48 hours following the initial application of diclofenac gel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only limited data on the efficacy of corticosteroids for sunburn.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Topical",
"    </span>",
"    &nbsp;&mdash;&nbsp;While some trials of topical corticosteroids appear to show benefit, these have generally not had placebo controls [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/70,72\">",
"     70,72",
"    </a>",
"    ]. One placebo-controlled trial in patients with sunburn found no benefit to treatment with fluocinolone cream [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/73\">",
"     73",
"    </a>",
"    ], and a second placebo-controlled trial found no clinically important benefit with either a moderate potency or a high potency topical corticosteroid [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combining topical corticosteroids with either topical or oral NSAIDs may be more efficacious than either agent alone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]; however, even the combined effect appears to be limited in duration of benefit and to exposures below those typically encountered in natural sunburn [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Systemic",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial in patients with experimental UVB exposure found no benefit to prednisone 80 mg given 24 hours before exposure, and then immediately after exposure, and then either 24 or 48 hours after exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Emollients",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are very few data on the use of emollients after sunburn [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study of aloe vera gel after UVB exposure did not appear to show benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/70\">",
"     70",
"    </a>",
"    ]. Topical antihistamines may produce minimal benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/70,78\">",
"     70,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Products containing topical anesthetics such as benzocaine (eg, Solarcaine&reg;, Lanacane&reg;) are advertised as being effective for sunburn. There is very little published evidence on their efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Any topical agent can cause allergic contact dermatitis, and there have been rare reports of photocontact allergy with topical preparations containing benzocaine, diphenhydramine, or diclofenac&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/80-83\">",
"     80-83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Symptomatic management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently, treatment of sunburn is only symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/13\">",
"     13",
"    </a>",
"    ]. Individuals should be advised to avoid further sun exposure until symptoms resolve.",
"   </p>",
"   <p>",
"    Application of moisturizing lotion or aloe vera gel and use of cold compresses or soaks in cool water may ease discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/70,84\">",
"     70,84",
"    </a>",
"    ]. Pain and pruritus may also be lessened by use of NSAIDs, acetaminophen, low-potency topical corticosteroids (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 3",
"    </a>",
"    ), or oral diphenhydramine until the sunburn heals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30136/abstract/70\">",
"     70",
"    </a>",
"    ]. If blistering of the skin is present, further measures may be taken to minimize the risk of secondary infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37479?source=see_link\">",
"     \"Treatment of minor thermal burns\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/20/23874?source=see_link\">",
"       \"Patient information: Sunburn (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/30/18913?source=see_link\">",
"       \"Patient information: Sunburn (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sunburn is common and is a marker for excess sun exposure, which is a risk factor for skin cancer. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sunburn is diagnosed by its typical appearance and a history of exposure. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be encouraged to take steps to prevent sunburn by limiting sun exposure, wearing protective clothing, and using sunscreen that protects against both UVA and UVB. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sunscreen should have an SPF of at least 30 and should be applied frequently (every two to three hours) and in the quantity recommended by the manufacturer. Most people do not apply adequate amounts of sunscreen to achieve the protection implied by the SPF. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Sunscreen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tanning has been associated with an increased risk of melanoma. Tanning should not be utilized as a method of preventing sunburn. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Tanning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of proof that any treatment for sunburn can speed healing or reverse damage, we suggest only symptomatic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This can include moisturizing lotions, cold compresses, NSAIDs, acetaminophen, low-potency topical corticosteroids (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 3",
"      </a>",
"      ), and oral diphenhydramine. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/1\">",
"      Saraiya M, Hall HI, Uhler RJ. Sunburn prevalence among adults in the United States, 1999. Am J Prev Med 2002; 23:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/2\">",
"      Davis KJ, Cokkinides VE, Weinstock MA, et al. Summer sunburn and sun exposure among US youths ages 11 to 18: national prevalence and associated factors. Pediatrics 2002; 110:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/3\">",
"      Geller AC, Colditz G, Oliveria S, et al. Use of sunscreen, sunburning rates, and tanning bed use among more than 10 000 US children and adolescents. Pediatrics 2002; 109:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/4\">",
"      Brown TT, Quain RD, Troxel AB, Gelfand JM. The epidemiology of sunburn in the US population in 2003. J Am Acad Dermatol 2006; 55:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/5\">",
"      Centers for Disease Control and Prevention (CDC). Sunburn prevalence among adults--United States, 1999, 2003, and 2004. MMWR Morb Mortal Wkly Rep 2007; 56:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/6\">",
"      van Dam RM, Huang Z, Rimm EB, et al. Risk factors for basal cell carcinoma of the skin in men: results from the health professionals follow-up study. Am J Epidemiol 1999; 150:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/7\">",
"      Walther U, Kron M, Sander S, et al. Risk and protective factors for sporadic basal cell carcinoma: results of a two-centre case-control study in southern Germany. Clinical actinic elastosis may be a protective factor. Br J Dermatol 2004; 151:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/8\">",
"      Kennedy C, Bajdik CD, Willemze R, et al. The influence of painful sunburns and lifetime sun exposure on the risk of actinic keratoses, seborrheic warts, melanocytic nevi, atypical nevi, and skin cancer. J Invest Dermatol 2003; 120:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/9\">",
"      Veier&oslash;d MB, Weiderpass E, Th&ouml;rn M, et al. A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women. J Natl Cancer Inst 2003; 95:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/10\">",
"      Matsumura Y, Ananthaswamy HN. Toxic effects of ultraviolet radiation on the skin. Toxicol Appl Pharmacol 2004; 195:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/11\">",
"      Kulms D, Schwarz T. Independent contribution of three different pathways to ultraviolet-B-induced apoptosis. Biochem Pharmacol 2002; 64:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/12\">",
"      Edwards EK Jr, Edwards EK Sr. Sunburn and sunscreens: an update and review. Mil Med 1990; 155:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/13\">",
"      Driscoll MS, Wagner RF Jr. Clinical management of the acute sunburn reaction. Cutis 2000; 66:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/14\">",
"      Deliconstantinos G, Villiotou V, Stavrides JC. Nitric oxide and peroxynitrite released by ultraviolet B-irradiated human endothelial cells are possibly involved in skin erythema and inflammation. Exp Physiol 1996; 81:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/15\">",
"      Mukamal KJ. Alcohol consumption and self-reported sunburn: a cross-sectional, population-based survey. J Am Acad Dermatol 2006; 55:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/16\">",
"      Rhainds M, De Guire L, Claveau J. A population-based survey on the use of artificial tanning devices in the Province of Qu&eacute;bec, Canada. J Am Acad Dermatol 1999; 40:572.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Safer sunning in seven steps. www.fda.gov/opacom/lowlit/sunsafty.pdf (Accessed 3/7/05).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/18\">",
"      Davis S, Capjack L, Kerr N, Fedosejevs R. Clothing as protection from ultraviolet radiation: which fabric is most effective? Int J Dermatol 1997; 36:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/19\">",
"      Edlich RF, Cox MJ, Becker DG, et al. Revolutionary advances in sun-protective clothing--an essential step in eliminating skin cancer in our world. J Long Term Eff Med Implants 2004; 14:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/20\">",
"      Moloney FJ, Collins S, Murphy GM. Sunscreens: safety, efficacy and appropriate use. Am J Clin Dermatol 2002; 3:185.",
"     </a>",
"    </li>",
"    <li>",
"     Rosen, CF. Sunscreens and the prevention of erythema. In: Sunscreen Photobiology: Molecular, Cellular, and Physiological Aspects, Gasparro, F (Ed), Springer-Verlag and Landes Bioscience, Berlin, Heidelberg, New York 1997. p.63-68.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/22\">",
"      Bernerd F, Vioux C, Lejeune F, Asselineau D. The sun protection factor (SPF) inadequately defines broad spectrum photoprotection: demonstration using skin reconstructed in vitro exposed to UVA, UVBor UV-solar simulated radiation. Eur J Dermatol 2003; 13:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/23\">",
"      Bissonnette R, Allas S, Moyal D, Provost N. Comparison of UVA protection afforded by high sun protection factor sunscreens. J Am Acad Dermatol 2000; 43:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/24\">",
"      Bernerd F, Vioux C, Asselineau D. Evaluation of the protective effect of sunscreens on in vitro reconstructed human skin exposed to UVB or UVA irradiation. Photochem Photobiol 2000; 71:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/25\">",
"      Lautenschlager S, Wulf HC, Pittelkow MR. Photoprotection. Lancet 2007; 370:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/26\">",
"      Lavker RM, Veres DA, Irwin CJ, Kaidbey KH. Quantitative assessment of cumulative damage from repetitive exposures to suberythemogenic doses of UVA in human skin. Photochem Photobiol 1995; 62:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/27\">",
"      Bernerd F, Asselineau D. UVA exposure of human skin reconstructed in vitro induces apoptosis of dermal fibroblasts: subsequent connective tissue repair and implications in photoaging. Cell Death Differ 1998; 5:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/28\">",
"      Patel NP, Highton A, Moy RL. Properties of topical sunscreen formulations. A review. J Dermatol Surg Oncol 1992; 18:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/29\">",
"      Diffey BL, Grice J. The influence of sunscreen type on photoprotection. Br J Dermatol 1997; 137:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/30\">",
"      A new sunscreen agent. Med Lett Drugs Ther 2007; 49:41.",
"     </a>",
"    </li>",
"    <li>",
"     www.aad.org/public/News/DermInfo/DInfoSunscreenFAQ.htm (Accessed 3/7/05).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/32\">",
"      Stokes R, Diffey B. How well are sunscreen users protected? Photodermatol Photoimmunol Photomed 1997; 13:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/33\">",
"      Autier P, Boniol M, Severi G, et al. Quantity of sunscreen used by European students. Br J Dermatol 2001; 144:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/34\">",
"      Stenberg C, Lark&ouml; O. Sunscreen application and its importance for the sun protection factor. Arch Dermatol 1985; 121:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/35\">",
"      Faurschou A, Wulf HC. The relation between sun protection factor and amount of suncreen applied in vivo. Br J Dermatol 2007; 156:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/36\">",
"      Pruim B, Green A. Photobiological aspects of sunscreen re-application. Australas J Dermatol 1999; 40:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/37\">",
"      Diffey BL. When should sunscreen be reapplied? J Am Acad Dermatol 2001; 45:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/38\">",
"      Autier P, Dor&eacute; JF, N&eacute;grier S, et al. Sunscreen use and duration of sun exposure: a double-blind, randomized trial. J Natl Cancer Inst 1999; 91:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/39\">",
"      Autier P, Dor&eacute; JF, Reis AC, et al. Sunscreen use and intentional exposure to ultraviolet A and B radiation: a double blind randomized trial using personal dosimeters. Br J Cancer 2000; 83:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/40\">",
"      Dupuy A, Dunant A, Grob JJ, R&eacute;seau d'Epid&eacute;miologie en Dermatologie. Randomized controlled trial testing the impact of high-protection sunscreens on sun-exposure behavior. Arch Dermatol 2005; 141:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/41\">",
"      Stumpf, JL. Myths and facts about sunscreen shelf life and SPF. US Pharm 2004; 8:73.",
"     </a>",
"    </li>",
"    <li>",
"     www.aap.org/advocacy/releases/summertips.cfm (Accessed on June 23, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/43\">",
"      Dobbinson S, Wakefield M, Hill D, et al. Prevalence and determinants of Australian adolescents' and adults' weekend sun protection and sunburn, summer 2003-2004. J Am Acad Dermatol 2008; 59:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/44\">",
"      Cokkinides VE, Weinstock MA, Cardinez CJ, O'Connel MA. Sun-safe practices in U.S. youth and their parents: role of caregiver on youth sunscreen use. Am J Prev Med 2004; 26:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/45\">",
"      Antille C, Tran C, Sorg O, et al. Vitamin A exerts a photoprotective action in skin by absorbing ultraviolet B radiation. J Invest Dermatol 2003; 121:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/46\">",
"      Lin JY, Selim MA, Shea CR, et al. UV photoprotection by combination topical antioxidants vitamin C and vitamin E. J Am Acad Dermatol 2003; 48:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/47\">",
"      Meves A, Stock SN, Beyerle A, et al. Vitamin C derivative ascorbyl palmitate promotes ultraviolet-B-induced lipid peroxidation and cytotoxicity in keratinocytes. J Invest Dermatol 2002; 119:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/48\">",
"      Greul AK, Grundmann JU, Heinrich F, et al. Photoprotection of UV-irradiated human skin: an antioxidative combination of vitamins E and C, carotenoids, selenium and proanthocyanidins. Skin Pharmacol Appl Skin Physiol 2002; 15:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/49\">",
"      Mireles-Rocha H, Galindo I, Huerta M, et al. UVB photoprotection with antioxidants: effects of oral therapy with d-alpha-tocopherol and ascorbic acid on the minimal erythema dose. Acta Derm Venereol 2002; 82:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/50\">",
"      Eberlein-K&ouml;nig B, Placzek M, Przybilla B. Protective effect against sunburn of combined systemic ascorbic acid (vitamin C) and d-alpha-tocopherol (vitamin E). J Am Acad Dermatol 1998; 38:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/51\">",
"      Katiyar SK, Elmets CA. Green tea polyphenolic antioxidants and skin photoprotection (Review). Int J Oncol 2001; 18:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/52\">",
"      Elmets CA, Singh D, Tubesing K, et al. Cutaneous photoprotection from ultraviolet injury by green tea polyphenols. J Am Acad Dermatol 2001; 44:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/53\">",
"      Lu YP, Lou YR, Li XH, et al. Stimulatory effect of oral administration of green tea or caffeine on ultraviolet light-induced increases in epidermal wild-type p53, p21(WAF1/CIP1), and apoptotic sunburn cells in SKH-1 mice. Cancer Res 2000; 60:4785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/54\">",
"      Record IR, Dreosti IE. Protection by black tea and green tea against UVB and UVA + B induced skin cancer in hairless mice. Mutat Res 1998; 422:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/55\">",
"      Conney AH, Wang ZY, Huang MT, et al. Inhibitory effect of green tea on tumorigenesis by chemicals and ultraviolet light. Prev Med 1992; 21:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/56\">",
"      Roser-Maass E, H&ouml;lzle E, Plewig G. Protection against UV-B by UV-A-induced tan. Arch Dermatol 1982; 118:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/57\">",
"      Bykov VJ, Marcusson JA, Hemminki K. Protective effects of tanning on cutaneous DNA damage in situ. Dermatology 2001; 202:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/58\">",
"      Gange RW, Blackett AD, Matzinger EA, et al. Comparative protection efficiency of UVA- and UVB-induced tans against erythema and formation of endonuclease-sensitive sites in DNA by UVB in human skin. J Invest Dermatol 1985; 85:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/59\">",
"      Kaidbey KH, Kligman AM. Sunburn protection by longwave ultraviolet radiation-induced pigmentation. Arch Dermatol 1978; 114:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/60\">",
"      Cokkinides V, Weinstock M, Lazovich D, et al. Indoor tanning use among adolescents in the US, 1998 to 2004. Cancer 2009; 115:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/61\">",
"      El Ghissassi F, Baan R, Straif K, et al. A review of human carcinogens--part D: radiation. Lancet Oncol 2009; 10:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/62\">",
"      International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review. Int J Cancer 2007; 120:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/63\">",
"      Seddon JM, Gragoudas ES, Glynn RJ, et al. Host factors, UV radiation, and risk of uveal melanoma. A case-control study. Arch Ophthalmol 1990; 108:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/64\">",
"      Vajdic CM, Kricker A, Giblin M, et al. Artificial ultraviolet radiation and ocular melanoma in Australia. Int J Cancer 2004; 112:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/65\">",
"      Faurschou A, Wulf HC. Durability of the sun protection factor provided by dihydroxyacetone. Photodermatol Photoimmunol Photomed 2004; 20:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/66\">",
"      Jung K, Seifert M, Herrling T, Fuchs J. UV-generated free radicals (FR) in skin: their prevention by sunscreens and their induction by self-tanning agents. Spectrochim Acta A Mol Biomol Spectrosc 2008; 69:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/67\">",
"      Sivamani RK, Crane LA, Dellavalle RP. The benefits and risks of ultraviolet tanning and its alternatives: the role of prudent sun exposure. Dermatol Clin 2009; 27:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/68\">",
"      Wickelgren I. Skin biology. A healthy tan? Science 2007; 315:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/69\">",
"      In search of the safe suntan. Getting a tan is bad for you, but having one might be protective--if no UV light were involved. Harv Health Lett 2007; 32:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/70\">",
"      Han A, Maibach HI. Management of acute sunburn. Am J Clin Dermatol 2004; 5:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/71\">",
"      Magnette J, Kienzler JL, Alekxandrova I, et al. The efficacy and safety of low-dose diclofenac sodium 0.1% gel for the symptomatic relief of pain and erythema associated with superficial natural sunburn. Eur J Dermatol 2004; 14:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/72\">",
"      Duteil L, Queille-Roussel C, Lorenz B, et al. A randomized, controlled study of the safety and efficacy of topical corticosteroid treatments of sunburn in healthy volunteers. Clin Exp Dermatol 2002; 27:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/73\">",
"      Russo PM, Schneiderman LJ. Effect of topical corticosteroids on symptoms of clinical sunburn. J Fam Pract 1978; 7:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/74\">",
"      Faurschou A, Wulf HC. Topical corticosteroids in the treatment of acute sunburn: a randomized, double-blind clinical trial. Arch Dermatol 2008; 144:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/75\">",
"      Eaglestein WH, Ginsberg LD, Mertz PM. Ultraviolet irradiation-induced inflammation: effects of steroid and nonsteroid anti-inflammatory agents. Arch Dermatol 1979; 115:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/76\">",
"      Hughes GS, Francom SF, Means LK, et al. Synergistic effects of oral nonsteroidal drugs and topical corticosteroids in the therapy of sunburn in humans. Dermatology 1992; 184:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/77\">",
"      Greenwald JS, Parrish JA, Jaenicke KF, Anderson RR. Failure of systemically administered corticosteroids to suppress UVB-induced delayed erythema. J Am Acad Dermatol 1981; 5:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/78\">",
"      Schaffler K, Beckers C, Unkauf M, Kyrein HJ. Dimethindene maleate in the treatment of sunburn. A double-blind, placebo-controlled pilot study. Arzneimittelforschung 1999; 49:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/79\">",
"      Dalili H, Adriani J. The efficacy of local anesthetics in blocking the sensations of itch, burning, and pain in normal and \"sunburned\" skin. Clin Pharmacol Ther 1971; 12:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/80\">",
"      Kaidbey KH, Allen H. Photocontact allergy to benzocaine. Arch Dermatol 1981; 117:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/81\">",
"      Yamada S, Tanaka M, Kawahara Y, et al. Photoallergic contact dermatitis due to diphenhydramine hydrochloride. Contact Dermatitis 1998; 38:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/82\">",
"      Kowalzick L, Ziegler H. Photoallergic contact dermatitis from topical diclofenac in Solaraze gel. Contact Dermatitis 2006; 54:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30136/abstract/83\">",
"      Montoro J, Rodr&iacute;guez M, D&iacute;az M, Bertomeu F. Photoallergic contact dermatitis due to diclofenac. Contact Dermatitis 2003; 48:115.",
"     </a>",
"    </li>",
"    <li>",
"     Center for Disease Control and Prevention (CDC) National Center for Environmental Health. Extreme heat: Sunburn. www.bt.cdc.gov/disasters/extremeheat/heat_guide.asp#sunburn (Accessed 3/7/05).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6624 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.97.94.19-BA627EFD15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_27_30136=[""].join("\n");
var outline_f29_27_30136=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SUSCEPTIBILITY AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      General issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sun protection factor (SPF)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Avoid UV exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clothing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sunscreen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      In children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Antioxidants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Tanning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Topical",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Systemic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Emollients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Symptomatic management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/6624\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/6624|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/4/24640\" title=\"picture 1A\">",
"      Sunburn back",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/6/19555\" title=\"picture 1B\">",
"      Sunburn blistering",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/6624|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/37/15963\" title=\"table 1\">",
"      Fitzpatrick skin phototypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/27/6589\" title=\"table 2\">",
"      Sunscreens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 3\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29831?source=related_link\">",
"      Approach to the patient with macular skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=related_link\">",
"      Epidemiology and clinical features of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15834?source=related_link\">",
"      Erythropoietic protoporphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=related_link\">",
"      New onset urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=related_link\">",
"      Overview of the clinical manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/30/18913?source=related_link\">",
"      Patient information: Sunburn (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/20/23874?source=related_link\">",
"      Patient information: Sunburn (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37479?source=related_link\">",
"      Treatment of minor thermal burns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_27_30137="The use of bisphosphonates in patients with multiple myeloma";
var content_f29_27_30137=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The use of bisphosphonates in patients with multiple myeloma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/27/30137/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/27/30137/contributors\">",
"     James R Berenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/27/30137/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/27/30137/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/27/30137/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/27/30137/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/27/30137/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/27/30137/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates are synthetic analogues to inorganic pyrophosphates found within the bone matrix that, unlike natural pyrophosphates, are resistant to hydrolysis by phosphatases found in the blood [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/1\">",
"     1",
"    </a>",
"    ]. Bisphosphonates inhibit bone resorption by suppressing osteoclast activity. They are widely used in the management of lytic bone lesions in patients with multiple myeloma (MM), in the treatment and prevention of osteoporosis, in the treatment of moderate to severe hypercalcemia, and in the therapy of certain other bone diseases.",
"   </p>",
"   <p>",
"    Lytic skeletal lesions are present at the time of diagnosis in approximately 60 percent of patients with MM and almost all patients with MM will have lytic bone lesions at some point in their disease course. In addition, up to 20 percent of patients with MM will have osteopenia and 10 to 15 percent will have hypercalcemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of bisphosphonate therapy in patients with MM will be presented here. The role of bisphosphonate therapy in the management of other disorders is presented separately, as are the specific side effects associated with each agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8042?source=see_link\">",
"     \"Osteoclast inhibition in the management of bone metastases from breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H487374\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the exact mechanism is unknown, bisphosphonates appear to inhibit bone resorption by suppressing osteoclast activity. Clinically, this translates into fewer lytic bone lesions and fewer skeletal events (eg, pathologic fracture) in patients with multiple myeloma. Bisphosphonates are attracted to calcium and calcium containing molecules, such as hydroxyapatite, which is the major calcium-containing mineral in bone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/2\">",
"     2",
"    </a>",
"    ]. Bone resorption by osteoclasts results in the exposure of molecules of hydroxyapatite within the lytic lesions. Bisphosphonates are attracted to the hydroxyapatite and accumulate in this space, thereby creating a high local concentration of drug and inhibiting further osteoclast activity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Although the exact half life is unknown, bisphosphonates that are incorporated into bone are thought to remain for at least 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two main classes of bisphosphonates, each with a different proposed mechanism of action [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/2\">",
"     2",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     Etidronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"     clodronate",
"    </a>",
"    are non-nitrogen containing bisphosphonates. Non-nitrogen containing bisphosphonates are metabolized to cytotoxic ATP analogues, incorporated into the osteoclast, and induce osteoclast apoptosis. In contrast, nitrogen containing bisphosphonates are proposed to suppress osteoclast activity by binding to and inhibiting the enzyme farnesyl diphosphate synthase in the HMG-CoA reductase pathway.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     Pamidronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    are examples of nitrogen-containing bisphosphonates.",
"   </p>",
"   <p>",
"    Bisphosphonates also appear to affect the microenvironment in which tumor cells grow and may have direct anti-tumor activity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27977?source=see_link&amp;anchor=H20#H20\">",
"     \"Pathobiology of multiple myeloma\", section on 'Bone marrow microenvironment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H488867\">",
"    <span class=\"h1\">",
"     BENEFITS OF BISPHOSPHONATES IN MYELOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates are an essential part of the management of skeletal lesions in patients with multiple myeloma (MM). While they do not repair existing bone damage, they prevent the development of new lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4723679\">",
"    <span class=\"h2\">",
"     Use in symptomatic MM",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with MM who have one or more lesions on skeletal radiographs, we recommend the use of bisphosphonate therapy, to be given in addition to other therapies directed at the malignant plasma cell clone. We also suggest the use of bisphosphonates for patients with MM who do not have lytic bone lesions on radiography but demonstrate osteopenia or osteoporosis on bone mineral density studies. While such patients haven&rsquo;t been included in studies of bisphosphonates, some clinicians also give bisphosphonates to patients with active MM requiring antimyeloma therapy who do not demonstrate lytic bone lesions on imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our decision to use bisphosphonates is based upon numerous prospective, randomized controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/12-21\">",
"     12-21",
"    </a>",
"    ] and two systematic reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/22,23\">",
"     22,23",
"    </a>",
"    ] that have demonstrated that bisphosphonates reduce the number of vertebral fractures, skeletal related events, and associated pain in patients with MM and skeletal lesions. While some studies have suggested a survival benefit in subpopulations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/12,13,15-18\">",
"     12,13,15-18",
"    </a>",
"    ], others have not [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. A 2012 Cochrane systematic review found that, when compared with placebo or no treatment, bisphosphonate therapy resulted in the following beneficial effects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prevention of pathological vertebral fractures (relative risk [RR] of 0.74, 95% CI 0.62-0.89)",
"     </li>",
"     <li>",
"      Fewer skeletal related events (RR 0.80, 95% CI 0.72-0.89)",
"     </li>",
"     <li>",
"      Better control of skeletal related pain (RR 0.75, 95% CI 0.60-0.95)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bisphosphonates did not appear to improve overall survival (hazard ratio [HR] 0.96, 95% CI 0.82-1.13) or progression-free survival (HR 0.71, 95% CI 0.41-1.19). However, there was significant heterogeneity among various bisphosphonates with respect to their effect on overall survival. There appeared to be a",
"    <span class=\"nowrap\">",
"     dose/potency",
"    </span>",
"    effect with a subset analysis suggesting improved survival with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    (HR 0.42, 95% CI 0.81-0.22).",
"   </p>",
"   <p>",
"    When assuming the baseline risk of vertebral fracture without treatment to be 20 to 50 percent, this analysis estimated that between 8 and 20 patients should be treated to prevent vertebral fracture in one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/23\">",
"     23",
"    </a>",
"    ]. Likewise, it estimated that between 5 and 13 patients should be treated to reduce pain in one patient. Since intravenous bisphosphonates have a beneficial impact on pain control, their use is recommended for patients with pain due to osteolytic disease, and as an adjunct to radiation therapy, analgesics, or surgical intervention to stabilize fractures or impending fractures. Pain control appears to take effect relatively rapidly. At least one study noted an onset of analgesia within approximately one week of beginning intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    in patients with symptomatic bone metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/27\">",
"     27",
"    </a>",
"    ]. Additional methods for managing skeletal events in patients with MM are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of the complications of multiple myeloma\", section on 'Skeletal lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guidelines for the use of bisphosphonates in MM have been issued by the American Society of Clinical Oncology (ASCO) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/28\">",
"     28",
"    </a>",
"    ], Mayo Clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/29\">",
"     29",
"    </a>",
"    ], International Myeloma Working Group (IMWG) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/30\">",
"     30",
"    </a>",
"    ], European Myeloma Network (EMN) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/2\">",
"     2",
"    </a>",
"    ], National Comprehensive Cancer Network (NCCN) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/31\">",
"     31",
"    </a>",
"    ], and European Society of Medical Oncology (ESMO) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/32\">",
"     32",
"    </a>",
"    ]. While the exact guidelines differ in detail, they all recognize a benefit from the use of bisphosphonates in MM patients with lytic bone lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4723667\">",
"    <span class=\"h2\">",
"     Use in asymptomatic MM, MGUS, or solitary plasmacytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates have not been proven to be beneficial for patients with monoclonal gammopathy of undetermined significance (MGUS), solitary plasmacytoma, or smoldering (asymptomatic) myeloma (SMM). Bisphosphonates should be used in these patients only if they have another indication for their use, such as osteoporosis or osteopenia on bone mineral density studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=see_link\">",
"     \"Diagnosis of monoclonal gammopathy of undetermined significance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16662?source=see_link\">",
"     \"Diagnosis and management of solitary extramedullary plasmacytoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44535?source=see_link\">",
"     \"Diagnosis and management of solitary plasmacytoma of bone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following prospective trials have evaluated the use of bisphosphonates in patients with smoldering myeloma or monoclonal gammopathy of undetermined significance (MGUS):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter, open-label phase III randomized trial compared one year of monthly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      infusions versus observation alone as the initial management of 163 patients with SMM [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/33\">",
"       33",
"      </a>",
"      ]. After a median follow-up of 5.4 years, approximately 45 percent of the patients in each group had progressed to symptomatic MM and there was no difference in the median time to progression.",
"     </li>",
"     <li>",
"      Similar results were noted in a multicenter, open-label phase III randomized trial that compared one year of monthly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      versus observation in 177 patients with SMM [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/34\">",
"       34",
"      </a>",
"      ]. The administration of pamidronate did not postpone progression to symptomatic myeloma, which was 63 percent at five years in both treatment groups. Patients who received pamidronate were less likely to have a skeletal-related event (osteolytic bone lesions, pathological fractures,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypercalcemia) at the time of progression.",
"     </li>",
"     <li>",
"      A prospective phase II open-label trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      every six months for one year in 54 patients with MGUS and osteopenia or osteoporosis reported improved bone mineral density after treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H487381\">",
"    <span class=\"h1\">",
"     RISKS OF BISPHOSPHONATE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged therapy with bisphosphonates is generally well tolerated. However, patients should be periodically monitored for a number of complications, including nephrotic syndrome, renal insufficiency, hypocalcemia, and osteonecrosis (avascular necrosis) of the jaw. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H488874\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before starting bisphosphonate therapy, patients must be evaluated to determine the extent of disease and to look for comorbidities that may alter the dosing and administration of these drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H488881\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrotoxicity and hypocalcemia are potential side-effects of bisphosphonate therapy. Serum levels of creatinine, calcium, and magnesium should be evaluated prior to the initiation of therapy and periodically thereafter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H2#H2\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Proteinuria and renal insufficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H488888\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies should be obtained prior to starting bisphosphonate therapy to document skeletal lytic lesions and act as a baseline for comparison after therapy. The preferred imaging modality for most patients is a metastatic bone survey with plain radiographs. Additional imaging studies may be indicated in certain populations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Radiographic studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H487388\">",
"    <span class=\"h2\">",
"     Dental exam",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dental procedures, such as extraction and placement of dental implants may be associated with osteonecrosis (avascular necrosis) of the jaw in patients treated with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    . However, less invasive procedures such as dental cleaning, cavity repairs, placement of crowns, and root canals are not thought to be risk factors for ONJ. It is prudent to advise patients to avoid these dental procedures while receiving intravenous bisphosphonates as well as to identify and rectify dental problems before treatment with these agents. As such, all patients should receive a comprehensive dental examination and appropriate preventive dentistry before starting treatment with bisphosphonates. Active oral infections should be treated and sites at high risk for infection should be eliminated. While on therapy, patients should maintain excellent oral hygiene and avoid invasive dental procedures, if possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H1928329#H1928329\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Osteonecrosis of the jaw'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H488895\">",
"    <span class=\"h1\">",
"     CHOICE OF AGENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective randomized trials have compared bisphosphonates with placebo or no treatment. There are limited data comparing specific bisphosphonate agents with each other, but those that exist have not found any one intravenously administered bisphosphonate to be more efficacious [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. An indirect comparison (network) meta-analysis, performed as part of a 2012 Cochrane systematic review evaluating data from 4766 patients, did not find any particular type of bisphosphonate to be superior to another in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/23\">",
"     23",
"    </a>",
"    ]. An exception was that this indirect comparison suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    was more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    or placebo alone, but no more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"     clodronate",
"    </a>",
"    . This analysis included data from the large randomized Medical Research Council trial (Myeloma IX) that demonstrated that, when administered in addition to anti-myeloma chemotherapy, long-term monthly administration of zoledronic acid reduced skeletal morbidity as well as improved median overall survival (50 versus 45 months) compared with treatment with daily oral clodronate, a weaker non-nitrogen containing bisphosphonate [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    have been approved by the US Food and Drug Administration for this indication.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"     Clodronate",
"    </a>",
"    is an alternative agent that has been approved worldwide, except in the United States, for either oral or intravenous use. Currently, the choice among agents is principally made based upon the patient&rsquo;s renal function, physician experience, route of delivery, and side effect profiles, although the results of the MRC (Myeloma IX) trial [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/36,37\">",
"     36,37",
"    </a>",
"    ] and the network meta-analysis from Cochrane [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/23\">",
"     23",
"    </a>",
"    ] suggest that differences in their efficacy may exist. As an example, zoledronic acid and oral clodronate are NOT recommended for use in patients with severe renal impairment (ie, serum creatinine &gt;3.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or estimated creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"    Such patients may be treated with pamidronate, possibly administered with a modified infusion time.",
"   </p>",
"   <p>",
"    Intravenous bisphosphonates have the advantage of greater bioavailability and higher levels of compliance, but require observation during administration. While early, mostly anecdotal data suggested a higher risk of osteonecrosis of the jaw following the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    , this may have been a reflection of the longer overall survival of patients treated in this era rather than a true difference related to the choice of bisphosphonate [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/29,30,38\">",
"     29,30,38",
"    </a>",
"    ]. The indirect comparison (network) meta-analysis performed by Cochrane did not show any difference in the incidence of osteonecrosis of the jaw between bisphosphonates [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H1928329#H1928329\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Osteonecrosis of the jaw'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following sections provide an overview of the published data regarding the use of each of these agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H487395\">",
"    <span class=\"h2\">",
"     Intravenous pamidronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    (90 mg over at least two hours) can be administered every three to four weeks for patients with multiple myeloma (MM) and lytic destruction of bone or spine compression fracture from osteopenia on plain radiograph or imaging studies. Shorter infusion times should be avoided. For patients with existing severe renal impairment (ie, serum creatinine &gt;3.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or estimated creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    and extensive bone disease, pamidronate should be administered over four to six hours, with consideration for a reduced initial dosage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H6#H6\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Management and prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    in MM was initially evaluated in a randomized trial of pamidronate versus placebo in 377 patients with stage III MM and at least one lytic lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients received standard antimyeloma therapy along with either placebo or pamidronate (90 mg) as a four-hour intravenous infusion given every four weeks for nine cycles. Patients were monitored for skeletal events, which included pathologic fracture, irradiation of or surgery on bone, and spinal cord compression. After a median follow-up of nine months, patients assigned to pamidronate therapy had a significantly lower rate of skeletal events (24 versus 41 percent). Pamidronate therapy was also associated with a significant reduction in bone pain.",
"   </p>",
"   <p>",
"    A later report from the same investigators extended the evaluation to 21 cycles of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/13\">",
"     13",
"    </a>",
"    ]. The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    was associated with a significantly lower number of skeletal events per patient per year (1.3 versus 2.2 with placebo). There was no improvement in overall survival in the pamidronate group as a whole. On subgroup analysis, there appeared to be a survival benefit for patients who also received second-line antimyeloma therapy (14 versus 21 months). These benefits appeared to be associated with reduced bone marrow plasmacytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lower doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    may be just as effective as the 90 mg dose, but require further study. A double-blind, multicenter trial of 504 patients with newly diagnosed, symptomatic MM randomly assigned therapy with pamidronate 90 mg versus 30 mg, each given as a 2.5-hour infusion once a month [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/38\">",
"     38",
"    </a>",
"    ]. The 30 mg dose resulted in similar improvement in quality of life measures, median time to first skeletal-related event (10.2 versus 9.2 months), median overall survival (48 versus 42 months), and median progression-free survival (22 versus 21 months). In a retrospective analysis, patients assigned to the 30 mg dose demonstrated a nonsignificant trend towards less renal toxicity and a lower incidence of osteonecrosis of the jaw.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H487402\">",
"    <span class=\"h2\">",
"     Intravenous zoledronic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    (4 mg over 15 minutes) can be administered every three to four weeks for patients with multiple myeloma (MM) and lytic destruction of bone or spine compression fracture from osteopenia on plain radiograph or imaging studies. Shorter infusion times should be avoided. Patients with pre-existing mild to moderate renal impairment (ie, estimated creatinine clearance 30 to 60",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    should receive a reduced dose of zoledronic acid without a change in infusion time or interval. Zoledronic acid is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for use in patients with severe renal impairment.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    in patients with osteolytic metastases (MM or breast cancer) was initially evaluated in a phase II trial of 280 patients who were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    (90 mg IV over two hours) or one of three different doses of zoledronic acid (0.4, 2.0 or 4.0 mg, IV over five minutes) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/14\">",
"     14",
"    </a>",
"    ]. Zoledronic acid at a dose of 2 or 4 mg but not 0.4 mg was at least as effective as pamidronate in reducing the need for radiation therapy for symptomatic progression of bone metastases; adverse events were similar in nature and frequency. However, the results of this study must be interpreted with caution as it was a randomized phase II trial with only 60 to 70 patients in each arm.",
"   </p>",
"   <p>",
"    Similar results were obtained in a randomized, double-blind phase III trial in 1648 patients with advanced MM or breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients were randomly assigned to receive one of two different doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    (4 or 8 mg administered IV initially over 5 minutes, but had to be increased to 15 minutes because of renal impairment (see below)) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    (90 mg IV over two hours); infusions were repeated every three to four weeks for 12 months. One published randomized trial (ZMAX) shows that among MM patients with at least one lytic lesion, the safety profile of infusing zoledronic acid at a 4 mg dose is similar between those receiving a 15- or 30-minute infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/39\">",
"     39",
"    </a>",
"    ]. All participants received a daily 500 mg calcium supplement and 400 to 500 IU of vitamin D throughout the study. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The proportion of patients with at least one skeletal event during the first 13 months of the study, and the median time to the first event (12 months) was similar in all three treatment groups.",
"     </li>",
"     <li>",
"      The proportion of patients who required therapeutic bone irradiation was significantly lower in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      4 mg group compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      (15 versus 20 percent).",
"     </li>",
"     <li>",
"      Both agents were equally well tolerated, and the most common adverse events were bone pain, nausea, fatigue, and fever. Although 12 percent of patients receiving 4 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      over a five-minute period developed deterioration of previously normal renal function, an increase in the infusion volume to 100 mL, and lengthening the infusion time to 15 minutes reduced the incidence of renal dysfunction to the same levels as with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      (8 and 9 percent, respectively). Long-term data (25 months of follow-up) showed equivalent renal effects (changes in creatinine) for zoledronic acid 4 mg over 15 minutes and pamidronate over two hours [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The 8 mg dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      had an unacceptably high incidence of renal toxicity at both infusion times (18 and 20 percent), and patients assigned to this arm had their dose reduced to 4 mg.",
"     </li>",
"     <li>",
"      Since the majority of patients in this study had normal renal function at study entry, it is unknown if longer infusion times would reduce renal damage among MM patients with renal impairment at baseline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A randomized trial from the Medical Research Council (Myeloma IX) of 1960 patients with previously untreated MM demonstrated that, when administered in addition to anti-myeloma chemotherapy, long term monthly administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    reduced the proportion of patients with skeletal related events (27 versus 35 percent) as well as improved overall survival (50 versus 45 months) compared with treatment with daily oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"     clodronate",
"    </a>",
"    , a weaker non-nitrogen containing bisphosphonate [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Both agents were well tolerated and had similar rates of acute renal failure and serious adverse events; zoledronic acid was associated with a higher rate of confirmed osteonecrosis of the jaw (4 versus &lt;1 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H488902\">",
"    <span class=\"h2\">",
"     Intravenous ibandronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    , monthly intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    has not demonstrated a reduction in skeletal-related events in patients with multiple myeloma (MM). Two randomized trials have evaluated the use of ibandronate in patients with MM:",
"   </p>",
"   <p>",
"    A randomized trial of 214 patients receiving conventional chemotherapy for stage II or III MM were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    (2 mg IV monthly for 24 months) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/24\">",
"     24",
"    </a>",
"    ]. Both the number and time to skeletal-related events were similar in the two study populations. The dose of ibandronate used in this study may have been too low; others have shown efficacy for 6 mg but not 2 mg monthly doses in patients with metastatic breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another randomized trial comparing monthly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    (4 mg) versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    (90 mg) in 44 patients with MM failed to demonstrate any difference in terms of incidence of skeletal-related events between the two agents, although pamidronate appeared to be more effective in reducing osteoclast activity, bone resorption, IL-6, and possibly tumour burden [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H487409\">",
"    <span class=\"h1\">",
"     ORAL BISPHOSPHONATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most bisphosphonates have poor oral absorption and have high rates of gastric toxicity (eg, gastritis, diarrhea) when administered by mouth. In the United States,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/51/38709?source=see_link\">",
"     tiludronate",
"    </a>",
"    &nbsp;are available in oral formulations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/42\">",
"     42",
"    </a>",
"    ]. In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"     clodronate",
"    </a>",
"    is available in some countries outside the United States. Although the newer bisphosphonates are more potent and allow for convenient outpatient dosing, the oral bioavailability is &lt;1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/43\">",
"     43",
"    </a>",
"    ]. Although not available in the United States, clodronate is the only oral bisphosphonate that has wide acceptance for use in patients with multiple myeloma (MM).",
"   </p>",
"   <p>",
"    Several large double-blind placebo-controlled clinical trials have been performed with oral bisphosphonates in MM:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 536 patients with newly diagnosed MM received either oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"       clodronate",
"      </a>",
"      (1600",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/17\">",
"       17",
"      </a>",
"      ]. Clodronate therapy was associated with a significantly lower incidence of vertebral (38 versus 55 percent) and nonvertebral fractures (6.8 versus 13.2 percent) but no difference in the incidence of symptomatic hypercalcemia [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/17\">",
"       17",
"      </a>",
"      ]. At a median follow-up of 8.6 years, there was no significant difference in survival between the two treatment groups. However, subgroup analysis suggested a survival benefit for those with no skeletal fractures at presentation who were treated with clodronate [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another randomized trial of 350 patients with MM demonstrated that, when compared with placebo,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"       clodronate",
"      </a>",
"      (2400",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      resulted in a significantly lower rate of radiologic skeletal progression at 24 months (12 versus 24 percent), but no significant improvement in fracture incidence or pain relief [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      (300",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      was compared with placebo in a trial of 300 patients with MM [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/20\">",
"       20",
"      </a>",
"      ]. No benefit was seen in terms of incidence of skeletal complications.",
"     </li>",
"     <li>",
"      Negative results were also obtained in a trial comparing oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"       etidronate",
"      </a>",
"      to placebo in 173 patients with MM [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As described above, a randomized trial from the Medical Research Council (Myeloma IX) of 1960 patients with previously untreated MM demonstrated that, when administered in addition to anti-myeloma chemotherapy, long-term monthly administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    reduced the proportion of patients with skeletal related events (27 versus 35 percent) as well as improved overall survival (50 versus 45 months) compared with treatment with daily oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"     clodronate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/36,37,44\">",
"     36,37,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"     clodronate",
"    </a>",
"    can be administered either as a 1600 mg daily dose or as 800 mg twice daily for patients with MM and lytic destruction of bone or spine compression fracture from osteopenia on plain radiograph or imaging studies. In order to maximize bioavailability, the pills must be taken on an empty stomach with fluid (not milk) at least one hour before and one hour after eating food. Oral clodronate is not recommended for use in patients with severe renal impairment (creatinine clearance &lt;12",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H490953\">",
"    <span class=\"h1\">",
"     MONITORING DURING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be periodically monitored for a number of complications, including nephrotic syndrome, renal insufficiency, hypocalcemia, and osteonecrosis (avascular necrosis) of the jaw. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum creatinine should be monitored before each dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    . The drug should be withheld in patients who develop renal deterioration with no other apparent cause. Treatment can be resumed cautiously once renal function returns to baseline. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H6#H6\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Management and prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While receiving bisphosphonate therapy, patients with multiple myeloma should undergo a 24-hour urine collection every three to six months to assess for the presence of albuminuria. Unexplained albuminuria (&gt;500",
"    <span class=\"nowrap\">",
"     mg/24",
"    </span>",
"    hours of urinary albumin) should prompt temporary discontinuation of bisphosphonate therapy. This occurs more often with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    -related nephrotoxicity than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    since pamidronate is more likely to cause glomerular damage, whereas zoledronic acid more often affects the tubules. Patients should be reassessed every three to four months with a 24-hour urine collection (for total protein and urine protein electrophoresis), and pamidronate reinstituted over a longer infusion duration (&ge;4 hours), at doses no greater than 90 mg every four weeks, when urine albumin levels and renal function (serum creatinine) returns to baseline.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The routine evaluation of biochemical markers of bone metabolism to monitor bisphosphonate use is",
"      <strong>",
"       not",
"      </strong>",
"      recommended. These markers are under evaluation in clinical trials for their ability to predict improvement in symptoms of pain and quality of life [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      While on therapy, patients should strive to maintain excellent oral hygiene and avoid invasive dental procedures, specifically dental extraction or implants. They should be encouraged to visit their dentist at least every six months for preventative care. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H1928329#H1928329\">",
"       \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Osteonecrosis of the jaw'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The International Myeloma Working Group has developed uniform response criteria, which are used to measure the effect of treatment for multiple myeloma. These criteria are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31526?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluating response to treatment of multiple myeloma\", section on 'Response criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H487423\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of bisphosphonate therapy for patients with multiple myeloma (MM) is unknown. Bisphosphonate treatment is frequently continued for five years or more in patients with osteoporosis, but the data on prolonged use in the setting of MM are limited. Randomized trials in this setting continued intravenous bisphosphonates for up to one year and oral bisphosphonates for two years or beyond [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/12-15,17-19,21,25,26\">",
"     12-15,17-19,21,25,26",
"    </a>",
"    ]. It is unclear if therapy beyond two years results in further skeletal benefits",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased toxicity.",
"   </p>",
"   <p>",
"    In the absence of randomized clinical trials, we suggest that treatment be given monthly for a period of two years. After two years, the decision to continue bisphosphonate therapy can be reassessed. Some experts would discontinue therapy after two years for patients who have attained a complete response, very good partial response, or stable plateau phase with no active bone disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/2,28-30\">",
"     2,28-30",
"    </a>",
"    ]. Bisphosphonate therapy can be continued if there is active bone disease or progressive myeloma. Most clinicians agree that bisphosphonates should be restarted upon relapse; however, some reinitiate bisphosphonates only in those with bone pain, those who develop progressive bone involvement at relapse, or those who experience a new skeletal complication. If the myeloma still requires treatment after two years, some clinicians decrease the frequency of bisphosphonate infusions to every three months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/29\">",
"     29",
"    </a>",
"    ]. There are no data from clinical trials to support either the recommendation to discontinue these drugs among patients without &ldquo;active bone disease&rdquo; or with responsive disease after two years of monthly treatment. There are also no data to suggest that schedules other than monthly administration of these drugs are effective. Randomized clinical trials are underway to determine whether longer-term bisphosphonate therapy is required, and whether less frequent dosing (eg, every three months versus every month) is adequate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31526?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluating response to treatment of multiple myeloma\", section on 'Response criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bisphosphonates have been thought of as supportive therapy aimed at decreasing the development of lytic bone lesions. They can be administered in conjunction with antimyeloma therapy directed at the plasma cell clone. These drugs do not appear to increase the toxicity of the currently used anti-myeloma agents. If the myeloma progresses during therapy, bisphosphonate therapy is continued while antimyeloma therapy is altered. Similarly, bisphosphonate therapy is continued if the patient has a skeletal event (eg, a compression fracture or pathologic fracture) since the drugs reduce the relative number but do not prevent these complications altogether [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/46\">",
"     46",
"    </a>",
"    ]. Bisphosphonates may not only prevent skeletal complications, but also improve the overall survival of patients with MM. This benefit was suggested in the MRC Myeloma IX trial, which demonstrated longer overall survival rates in patients with previously untreated MM who received monthly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    , when compared with patients who received oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"     clodronate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link\">",
"     \"Determination of initial therapy in patients with multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=see_link\">",
"     \"Treatment of relapsed or refractory multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H487430\">",
"    <span class=\"h1\">",
"     SOCIETY GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the use of bisphosphonates in multiple myeloma (MM) have been issued by the American Society of Clinical Oncology (ASCO) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/28\">",
"     28",
"    </a>",
"    ], Mayo clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/29\">",
"     29",
"    </a>",
"    ], International Myeloma Working Group (IMWG) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/30\">",
"     30",
"    </a>",
"    ], European Myeloma Network (EMN) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/2\">",
"     2",
"    </a>",
"    ], National Comprehensive Cancer Network (NCCN) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/31\">",
"     31",
"    </a>",
"    ], European Society of Medical Oncology (ESMO) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/32\">",
"     32",
"    </a>",
"    ], and British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30137/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/16/12547?source=see_link\">",
"       \"Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/40/31366?source=see_link\">",
"       \"Patient information: Multiple myeloma treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H488909\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with MM who have one or more lesions on skeletal radiographs, we recommend the use of intravenous monthly bisphosphonate therapy, to be given in addition to other therapies directed at the malignant plasma cell clone (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H488867\">",
"       'Benefits of bisphosphonates in myeloma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We also suggest the use of intravenous monthly bisphosphonates for patients with MM who do not have lytic bone lesions on radiography but demonstrate osteopenia or osteoporosis on bone mineral density studies (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H488867\">",
"       'Benefits of bisphosphonates in myeloma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Further investigation is required before the widespread application of bisphosphonates for patients with smoldering myeloma and for patients with MGUS plus osteopenia or osteoporosis. (See",
"      <a class=\"local\" href=\"#H488867\">",
"       'Benefits of bisphosphonates in myeloma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional methods for managing skeletal events in patients with myeloma are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of the complications of multiple myeloma\", section on 'Skeletal lesions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Once initiated, bisphosphonate therapy should be continued for a period of two years, at which time consideration may be given for stopping bisphosphonates in those with responsive or stable disease, although this may be associated with additional skeletal risk. For those in whom bisphosphonates were stopped after two years, the drug should be resumed on a monthly basis with the development of any new skeletal-related events. (See",
"      <a class=\"local\" href=\"#H487423\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/1\">",
"      Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88:2961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/2\">",
"      Terpos E, Sezer O, Croucher PI, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009; 20:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/3\">",
"      Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep MM, et al. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1986; 1:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/4\">",
"      Rowe DJ, Etre LA, Lovdahl MJ, Pietrzyk DJ. Relationship between bisphosphonate concentration and osteoclast activity and viability. In Vitro Cell Dev Biol Anim 1999; 35:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/5\">",
"      Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 2007; 86:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/6\">",
"      Mundy GR, Yoneda T. Bisphosphonates as anticancer drugs. N Engl J Med 1998; 339:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/7\">",
"      Yin JJ, Selander K, Chirgwin JM, et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999; 103:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/8\">",
"      Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/9\">",
"      Aparicio A, Gardner A, Tu Y, et al. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998; 12:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/10\">",
"      Shipman CM, Rogers MJ, Apperley JF, et al. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 1997; 98:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/11\">",
"      Dhodapkar MV, Singh J, Mehta J, et al. Anti-myeloma activity of pamidronate in vivo. Br J Haematol 1998; 103:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/12\">",
"      Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996; 334:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/13\">",
"      Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998; 16:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/14\">",
"      Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001; 91:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/15\">",
"      Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/16\">",
"      Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/17\">",
"      McCloskey EV, MacLennan IC, Drayson MT, et al. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 1998; 100:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/18\">",
"      McCloskey EV, Dunn JA, Kanis JA, et al. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 2001; 113:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/19\">",
"      Lahtinen R, Laakso M, Palva I, et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 1992; 340:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/20\">",
"      Brincker H, Westin J, Abildgaard N, et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. Br J Haematol 1998; 101:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/21\">",
"      Laakso M, Lahtinen R, Virkkunen P, Elomaa I. Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Br J Haematol 1994; 87:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/22\">",
"      Ross JR, Saunders Y, Edmonds PM, et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003; 327:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/23\">",
"      Mhaskar R, Redzepovic J, Wheatley K, et al. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev 2012; 5:CD003188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/24\">",
"      Menssen HD, Sakalov&aacute; A, Fontana A, et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 2002; 20:2353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/25\">",
"      Belch AR, Bergsagel DE, Wilson K, et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991; 9:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/26\">",
"      Daragon A, Humez C, Michot C, et al. Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Groupe d'Etudes et de Recherches sur le My&eacute;lome (GERM). Eur J Med 1993; 2:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/27\">",
"      Petcu EB, Schug SA, Smith H. Clinical evaluation of onset of analgesia using intravenous pamidronate in metastatic bone pain. J Pain Symptom Manage 2002; 24:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/28\">",
"      Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007; 25:2464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/29\">",
"      Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006; 81:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/30\">",
"      Durie BG. Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clin Proc 2007; 82:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/31\">",
"      Anderson KC, Alsina M, Bensinger W, et al. Multiple myeloma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007; 5:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/32\">",
"      Harrouseau JL, Greil R, Kloke O, ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of multiple myeloma. Ann Oncol 2005; 16 Suppl 1:i45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/33\">",
"      Musto P, Petrucci MT, Bringhen S, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008; 113:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/34\">",
"      D'Arena G, Gobbi PG, Broglia C, et al. Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leuk Lymphoma 2011; 52:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/35\">",
"      Berenson JR, Yellin O, Boccia RV, et al. Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss. Clin Cancer Res 2008; 14:6289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/36\">",
"      Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010; 376:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/37\">",
"      Morgan GJ, Davies FE, Gregory WM, et al. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. Blood 2012; 119:5374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/38\">",
"      Gimsing P, Carlson K, Turesson I, et al. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol 2010; 11:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/39\">",
"      Berenson JR, Boccia R, Lopez T, et al. Results of a multicenter open-label randomized trial evaluating infusion duration of zoledronic acid in multiple myeloma patients (the ZMAX trial). J Support Oncol 2011; 9:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/40\">",
"      Body JJ, Lichinitser MR, Diehl I, et al. Double-blind placebo-controlled trial of intravenous ibandronate in breast cancer metastatic to bone (abstract). Proc Am Soc Clin Oncol 1999; 35:575a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/41\">",
"      Terpos E, Viniou N, de la Fuente J, et al. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. Eur J Haematol 2003; 70:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/42\">",
"      Major PP, Lipton A, Berenson J, Hortobagyi G. Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer 2000; 88:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/43\">",
"      Daley-Yates PT, Dodwell DJ, Pongchaidecha M, et al. The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. Calcif Tissue Int 1991; 49:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/44\">",
"      Morgan GJ, Child JA, Gregory WM, et al. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol 2011; 12:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/45\">",
"      Vinholes JJ, Purohit OP, Abbey ME, et al. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 1997; 8:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/46\">",
"      Kyle RA. The role of bisphosphonates in multiple myeloma. Ann Intern Med 2000; 132:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30137/abstract/47\">",
"      Bird JM, Owen RG, D'Sa S, et al. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 2011; 154:32.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6663 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-74CF0474CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_27_30137=[""].join("\n");
var outline_f29_27_30137=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H488909\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H487374\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H488867\">",
"      BENEFITS OF BISPHOSPHONATES IN MYELOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4723679\">",
"      Use in symptomatic MM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4723667\">",
"      Use in asymptomatic MM, MGUS, or solitary plasmacytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H487381\">",
"      RISKS OF BISPHOSPHONATE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H488874\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H488881\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H488888\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H487388\">",
"      Dental exam",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H488895\">",
"      CHOICE OF AGENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H487395\">",
"      Intravenous pamidronate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H487402\">",
"      Intravenous zoledronic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H488902\">",
"      Intravenous ibandronate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H487409\">",
"      ORAL BISPHOSPHONATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H490953\">",
"      MONITORING DURING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H487423\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H487430\">",
"      SOCIETY GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H488909\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=related_link\">",
"      Determination of initial therapy in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16662?source=related_link\">",
"      Diagnosis and management of solitary extramedullary plasmacytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44535?source=related_link\">",
"      Diagnosis and management of solitary plasmacytoma of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=related_link\">",
"      Diagnosis of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31526?source=related_link\">",
"      Evaluating response to treatment of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8042?source=related_link\">",
"      Osteoclast inhibition in the management of bone metastases from breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27977?source=related_link\">",
"      Pathobiology of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/16/12547?source=related_link\">",
"      Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/40/31366?source=related_link\">",
"      Patient information: Multiple myeloma treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=related_link\">",
"      Treatment of relapsed or refractory multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=related_link\">",
"      Treatment of the complications of multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_27_30138="Virology, epidemiology, and transmission of human herpesvirus 8 infection";
var content_f29_27_30138=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Virology, epidemiology, and transmission of human herpesvirus 8 infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/27/30138/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/27/30138/contributors\">",
"     Corey Casper, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/27/30138/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/27/30138/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/27/30138/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/27/30138/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/27/30138/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kaposi's sarcoma, an unusual skin tumor localized in the lower extremities of elderly Mediterranean or Ashkenazi Jewish men, was first described in 1872 by the pathologist Moritz Kaposi [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/1\">",
"     1",
"    </a>",
"    ]. This malignancy was relatively rare until the early 1980s when, with the onset of the HIV epidemic, it was described in several homosexual men in North America [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology of Kaposi's sarcoma (KS) suggested a link between the development of disease and a transmissible agent. In 1994, a novel gamma herpesvirus was subsequently identified in KS biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/4\">",
"     4",
"    </a>",
"    ]. After sequence analysis of the genome and characterization of the viral replication cycle, this virus was subsequently named human herpesvirus 8 (HHV-8) or Kaposi's sarcoma-associated herpesvirus (KSHV).",
"   </p>",
"   <p>",
"    There are four epidemiologic forms of KS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Classic &mdash; Classic KS is an indolent cutaneous proliferative disease, mainly affecting the lower extremities of elderly men of Mediterranean and Jewish origin [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Endemic or African &mdash; The endemic or African form of KS found in all parts of equatorial Africa, particularly in sub-Saharan Africa. It is not typically associated with immune deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Iatrogenic or organ transplant-associated &mdash; KS may occur after solid organ transplantation and is often caused by transmission of HHV-8 from donor progenitor cells, although reactivation of latent HHV-8 in the recipient has also been described. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Solid organ transplantation'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19192?source=see_link&amp;anchor=H9#H9\">",
"       \"Disease associations of human herpesvirus 8 infection\", section on 'Solid organ transplantation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      AIDS-related or epidemic &mdash; KS is the most common tumor arising in HIV-infected persons, and is considered an AIDS-defining illness in the Centers for Disease Control and Prevention (CDC) guidelines. In the United States, KS is over 20,000 times more common in persons with AIDS than in the general population and over 300 times more common in AIDS than in other immunosuppressed hosts, such as renal transplant recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=see_link\">",
"       \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=see_link\">",
"       \"AIDS-related Kaposi sarcoma: Staging and treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The viral pathogenesis, epidemiology and transmission of HHV-8 infection will be reviewed here. The disease associations, diagnosis, and treatment of this virus are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19192?source=see_link\">",
"     \"Disease associations of human herpesvirus 8 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6743?source=see_link\">",
"     \"Diagnosis and antiviral therapy of human herpesvirus 8 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VIROLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-8 fits most closely into the family of human gamma herpesviruses, which includes Epstein-Barr virus. Gamma herpesviruses play an important role in cellular proliferation and the development of malignancies.",
"   </p>",
"   <p>",
"    The following discussion will emphasize important issues in the viral and pathogenesis of HHV-8 infection. As the pathogenesis of HHV-8 becomes more defined, molecular therapies may be used to target points along the pathway from primary infection to malignancy. Issues related to patients with concurrent HIV infection who might develop KS are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Viral entry into host cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-8 infects a wide variety of cell types, including B cells, endothelial cells, macrophages, and epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. This broad cellular tropism may be due to the interaction between HHV-8 and a ubiquitous host cell-surface molecule. The highly conserved envelope glycoprotein B (gB) of HHV-8 binds to heparan sulfate-like molecules in cellular targets to initiate adhesion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/13\">",
"     13",
"    </a>",
"    ]. A number of putative cellular receptors for HHV-8 have been defined, including integrin alpha3beta1 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/11\">",
"     11",
"    </a>",
"    ], DC-SIGN [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/14\">",
"     14",
"    </a>",
"    ], and the transmembrane light chain of the human",
"    <span class=\"nowrap\">",
"     cystine/glutamate",
"    </span>",
"    exchange transporter system x-c (xCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Lytic replication",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with all herpesviruses, the HHV-8 replication cycle includes both latent and lytic phases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/16\">",
"     16",
"    </a>",
"    ]. In studies of transformed cell lines, latent virus can be \"induced\" to upregulate viral replication and expression [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/17\">",
"     17",
"    </a>",
"    ]. In the lytic phase, the virus produces a wide range of structural and replicative gene products that lead to the production of intact virions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Much research has focused on understanding viral gene expression and the events leading to activation of lytic infection. The following represents a sample of the observations that have been made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An early gene encoded by HHV-8 (orf50) activates latent virus to the lytic phase. This gene is homologous to Rta, a transcriptional activator of Epstein-Barr virus [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cytokines and other co-factors that may induce HHV-8 replication include oncostatin M, hepatocyte growth factor, interferon-gamma, and the presence of tissue hypoxia [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/19-21\">",
"       19-21",
"      </a>",
"      ]. In comparison, interferon-alpha may act as an inhibitor [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/20,22\">",
"       20,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The induction of the HHV-8 lytic cycle may be influenced by other cofactors, including HIV-associated inflammatory cytokines [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. In one study, HIV-infected T cells were cocultured with an HHV-8 infected cell line [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/19\">",
"       19",
"      </a>",
"      ]. Several cytokines known to be important in growth and proliferation of KS induced HHV-8 lytic replication when added to the microenvironment.",
"     </li>",
"     <li>",
"      Micro RNAs (miRNA) may reduce the activity of NF&kappa;B and subsequently lead to lytic viral replication [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Epigenetic histone modifications of the HHV-8 genome have been found to play a role in the regulation of latency and in the orderly activation of the lytic program [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It is increasingly recognized that viruses have complex interactions with toll-like receptors (TLR), with profound effects on viral replication and immunity. Engagement of TLR-7 and TLR-8 result in the production of HHV-8 virions [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/27\">",
"       27",
"      </a>",
"      ]. These receptors can be activated by viruses, and suggest a role for viral coinfections in the lytic activation of KSHV.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458573284\">",
"    <span class=\"h2\">",
"     Host immune response and control of HHV-8 infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical observations suggest that T-cells play an important role in the control of KS, as evidenced by the increased incidence of KS among transplant recipients and AIDS patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/28\">",
"     28",
"    </a>",
"    ], the regression of KS with the reduction of immunosuppressive treatment following transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], and clinical improvement of KS in subjects with immune reconstitution following antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These clinical observations are supported by the following in vitro experiments examining the role of T cells and the recognition of HHV-8 epitopes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When comparing groups of patients with HHV-8 infection, impaired cytotoxic T-cell responses are seen among those with KS compared with asymptomatic individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Initiation of antiretroviral therapy in HIV-infected patients leads to improved T-cell responses to HHV-8 epitopes [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/34-37\">",
"       34-37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Impairment of CD8+ T cell responses at baseline is associated with an increased risk of developing KS over time [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/35\">",
"       35",
"      </a>",
"      ], and the depth of T cell depletion is associated with the incidence of KS [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these studies argue convincingly for the importance of cytotoxic T-cells in controlling HHV-8 infection, additional evidence also supports a role for natural killer (NK) cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/39\">",
"     39",
"    </a>",
"    ] and neutralizing antibodies in control of KS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Evasion of the host immune response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viruses, like HHV-8, have evolved mechanisms that modulate different aspects of the host immune response to their survival advantage, as illustrated by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Innate immunity:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Primary infection with HHV-8 is inhibited by TLR-4 activity, and endothelial cells lacking TLR-4 have an increased susceptibility to HHV-8 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/41\">",
"       41",
"      </a>",
"      ]. The virus&rsquo;s G protein-coupled receptor (vGPCR) and interferon regulatory factor-1 (vIRF-1) both serve to reduce the expression of TLR-4, increasing susceptibility to infection. Similarly, infection with HHV-8 leads to increased expression of TLR-3, which may induce a potent interferon antiviral effect [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HHV-8 produces at least four viral interferon regulatory factors (vIRF), which can downregulate the production of interferon (IFN)-alpha and IFN-beta, important components of innate immunity.",
"     </li>",
"     <li>",
"      Viral macrophage inflammatory protein (vMIP-II) blocks mobilization of the antiviral responses of Th1-like T lymphocytes and monocytes in vitro, while engaging other receptors (CCR3) that favor the recruitment of Th2 lymphocytes to KS lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T-cell immunity:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Downregulation of major histocompatibility complex (MHC) class I molecules by HHV-8 genes (K3 and K5) has also been demonstrated, a change that impairs antigen presentation to T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/44,45\">",
"       44,45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Viral gene product (K5) reduces ICAM-1 surface expression on HHV-8 infected B cells, which impairs T cell activation [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HHV-8 can avoid apoptosis through production of virally encoded antiapoptotic proteins, which may contribute to tumorigenesis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/47-49\">",
"       47-49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Control of the cell cycle and oncogenic transformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several viral gene products of HHV-8 are able to affect both cell cycle regulation and the control of apoptosis. HHV-8 contains viral oncogenes that are important in the pathogenesis of tumor formation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HHV-8 can transform primary human endothelial cells, which are the cells affected in KS [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      LANA-1, a latent nuclear antigen of HHV-8, may contribute to oncogenesis by targeting the retinoblastoma protein (pRB) transcriptional regulatory pathway [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HHV-8 encodes cyclin K, which inhibits the transcription of oncostatin M, a protein with growth-suppressive effects that prevent tumorigenesis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Viral interferon regulatory factor induces cellular transformation and prevents apoptosis mediated by p53 tumor suppressor, thereby facilitating uncontrolled cellular proliferation [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/53,54\">",
"       53,54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Viral IL-6 blocks host production of IFN-alpha, preventing the cell cycle arrest that is normally triggered by this cytokine [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HHV-8 encodes a G protein-coupled receptor (vGPCR) that induces multifocal KS-like lesions in transgenic mice. vGPCR may induce transformation via activation of nuclear factor-kappa B and induction of proinflammatory cytokines [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/56-58\">",
"       56-58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HHV-8 induces genetic reprogramming of both vascular and lymphatic cells so that they more closely resemble each other as opposed to their corresponding uninfected phenotypes [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/59,60\">",
"       59,60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The genome of HHV-8 contains an unprecedented number of open reading frames that were \"pirated\" during viral evolution from cellular genes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/61\">",
"     61",
"    </a>",
"    ]. Segments of the HHV-8 genome encode proteins that have homology to IL-6, the MIP-1 family of chemokines and active cell cycle regulators of the cyclin family [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/53,62-64\">",
"     53,62-64",
"    </a>",
"    ]. IL-6 may have direct mitogenic and angiogenic effects, while MIP-1 proteins may enhance these effects via chemotactic recruitment of endogenous cytokine-producing cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/53,65\">",
"     53,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Risk factors for disease progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since KS lesions are associated with proinflammatory cytokines, host genetic factors have been studied to determine if certain HLA backgrounds or immunomodulating genes may be risk factors for disease progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     HLA background",
"    </span>",
"    &nbsp;&mdash;&nbsp;KS has been associated with HLA-DR5 among Mediterranean men with classic [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/66-68\">",
"     66-68",
"    </a>",
"    ], or AIDS-associated KS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/69\">",
"     69",
"    </a>",
"    ], but not Israeli men with classic KS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/70,71\">",
"     70,71",
"    </a>",
"    ] or Africans with endemic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/72\">",
"     72",
"    </a>",
"    ]. Epidemic KS was also inversely associated with HLA-B14 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/73\">",
"     73",
"    </a>",
"    ], and positively associated with HLA-DB1 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/74\">",
"     74",
"    </a>",
"    ]. These confusing results may be a consequence of HLA background being too crude an indicator of genetic susceptibility to KS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Immunomodulating genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-8 has been shown to produce a viral analogue of human interleukin-6 (IL-6), which has been implicated in the development of KS and Castleman disease. Viral IL-6, which binds to human IL-6 cellular receptors, has a number of inflammatory and angiogenic properties [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/75\">",
"     75",
"    </a>",
"    ]. A single nucleotide polymorphism in the human IL-6 gene promoter has been described that is associated with increased IL-6 production (\"proinflammatory phenotype\") [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/76\">",
"     76",
"    </a>",
"    ]. Among a small group of Americans with epidemic KS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/77\">",
"     77",
"    </a>",
"    ], Greeks who developed KS after renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/78\">",
"     78",
"    </a>",
"    ], or immunocompetent Israelis with a familiar cluster of classic KS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/79\">",
"     79",
"    </a>",
"    ], the proinflammatory IL-6 phenotype was significantly more common.",
"   </p>",
"   <p>",
"    In a population based study in Italy, sequencing for common genetic variants of 14 immunomodulating genes demonstrated that polymorphisms in IL-8R were associated with a lower risk of classic KS while diplotypes of IL-13 were associated with a higher risk of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Replicating virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies also support a role for replicating HHV-8 in the pathogenesis of KS. In prospective clinical trials of intravenous [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/81\">",
"     81",
"    </a>",
"    ] and high-dose oral [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/82\">",
"     82",
"    </a>",
"    ]&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    for the treatment of AIDS-associated cytomegalovirus disease, the rate of new KS development was reduced by 40 and 75 percent, respectively, among antiviral drug recipients. As ganciclovir is only active against replicating HHV-8, theses studies provide indirect evidence for the role of replicating HHV-8 in the development of KS and suggest that KS can be prevented in high-risk patients. Furthermore, the detection of HHV-8 in plasma (indicating a lytic state of infection) has been associated with subsequent development of KS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/83-88\">",
"     83-88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HHV-8 replication is essential for the persistence of latent HHV-8 in spindle cells, which are a primary component of KS lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/89\">",
"     89",
"    </a>",
"    ]. The relationships between host and viral factors that lead to uncontrolled viral replication have not been characterized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Latent HHV-8 infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;While in latency, the virus exists as circular episomal DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/61\">",
"     61",
"    </a>",
"    ] and expresses limited gene products, including LANA-1, v-cyclin, and v-FLIP. Latency is common in a variety of cell types including B lymphocytes and glandular epithelial cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of serologic tests permitted evaluation of the epidemiology of HHV-8. While these tests have important limitations in both sensitivity and specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/90,91\">",
"     90,91",
"    </a>",
"    ], they have allowed for important observations regarding the epidemiology of HHV-8 infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6743?source=see_link\">",
"     \"Diagnosis and antiviral therapy of human herpesvirus 8 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Besides having different prevalence rates in different geographic regions, the specific risk groups for seropositivity appear to vary depending upon the location. The following discussion relates to the epidemiology of HHV-8 in various geographic regions. The epidemiology of AIDS-associated KS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     North America and northern Europe",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the beginning of the AIDS epidemic, it was noted that KS was primarily a disease affecting gay and bisexual men. Serologic testing for HHV-8 has demonstrated that men who have sex with men (MSM) were at special risk for infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum samples from 13,894 adults in the National Health and Nutrition Examination Survey were assayed for antibodies to HHV-8 structural and regulatory proteins [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/91\">",
"       91",
"      </a>",
"      ]. Seroprevalence in MSM was six-fold higher than in heterosexual individuals and was associated with an increasing number of sexual partners. Seroprevalence rates in MSM varied from 8 to 25 percent depending on the cut-off of the assay used.",
"     </li>",
"     <li>",
"      In HIV-seropositive MSM, between 30 and 77 percent test positive for HHV-8 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/63-65,92-94\">",
"       63-65,92-94",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, infection in the general population appears to be less common. Initial studies found that 1 to 3 percent of random blood donors are seropositive for HHV-8 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/65,95,96\">",
"     65,95,96",
"    </a>",
"    ]. More recent studies with more sensitive serologic assays have found that up to 30 percent of some blood donor populations have serum antibodies to HHV-8 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women and children were generally considered to be at low risk for infection. A 1997 study in 302 HIV-seropositive and 84 HIV-seronegative women found a 4 and 1 percent seroprevalence for HHV-8, respectively, using an immunofluorescence assay (IFA) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/98\">",
"     98",
"    </a>",
"    ]. However, a subsequent study of 1295 women in four urban cities found that seroprevalence varied with risk factors for acquisition [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/99\">",
"     99",
"    </a>",
"    ]. Seroprevalence was zero in women who were at low risk for sexual transmission and had never injected drugs. On the other hand, daily injection drug use, syphilis (as a marker of sexually transmitted disease), and HIV infection were, on multivariate analysis, associated with an odds ratio for HHV-8 of 3.2, 1.8, and 1.6, respectively. Adolescents with or at high risk of acquiring HIV in the United States, especially males who have sex with males and females who have sex with females, also have been found to have a higher prevalence of HHV-8 infection than the general population (up to 19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Mediterranean",
"    </span>",
"    &nbsp;&mdash;&nbsp;KS was originally described as an uncommon skin tumor occurring in elderly men of Mediterranean or Ashkenazi Jewish origin. A serologic survey was conducted in Sardinia, which has one of the world's highest incidence rates of KS. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The HHV-8 seroprevalence was 35 percent in Sardinia compared to 19 percent in Italy overall [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/101\">",
"       101",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibodies were detected two to three times more frequently in males than in females, which reflects the clinical observation that classic KS occurs mainly in men.",
"     </li>",
"     <li>",
"      Family members (both male and female) of KS patients had a three-fold higher HHV-8 seroprevalence compared to the general population, suggesting that clustering of HHV-8 may occur within families [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/102,103\">",
"       102,103",
"      </a>",
"      ]. The mechanism of increased seropositivity within families is unknown, but horizontal transmission may be responsible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Africa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even prior to the HIV epidemic, KS was known to be a relatively common tumor in Africa, with distinguishing clinical features compared to other parts of the world. The tumor is clinically more invasive and extensive, resulting in greater morbidity and mortality, even in HIV-seronegative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/104\">",
"     104",
"    </a>",
"    ]. Children and women are often affected.",
"   </p>",
"   <p>",
"    Serologic testing has shown a high seroprevalence in many regions of Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/8,63,95,105-112\">",
"     8,63,95,105-112",
"    </a>",
"    ]. The range of findings is demonstrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HHV-8 infection among newborns is uncommon, making vertical transmission unlikely. Seroprevalence appears to increase steadily with age, with the majority of persons infected prior to the onset of puberty [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/8,107,110,113\">",
"       8,107,110,113",
"      </a>",
"      ]. These findings suggest horizontal transmission to be the predominant mode of acquisition, although the continuous increase in seroprevalence observed beyond puberty indicates that sexual transmission may also occur in endemic areas [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/114\">",
"       114",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a large population-based study in rural Uganda, HHV-8 seroprevalence increased with increasing age [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/110\">",
"       110",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Age 1.5 to 2 years &ndash; 16 percent",
"     </li>",
"     <li>",
"      Age 10 to 13 years &ndash; 32 percent",
"     </li>",
"     <li>",
"      Age 14 to 19 years &ndash; 37 percent",
"     </li>",
"     <li>",
"      Age &ge;50 years &ndash; 49 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 42 percent of pregnant women and 52 percent of commercial sex workers in the Cameroon were seropositive for HHV-8 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/105\">",
"       105",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, approximately 50 percent of HIV-seropositive and seronegative individuals in Uganda had serologic evidence of HHV-8 infection [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/95\">",
"       95",
"      </a>",
"      ]. There was no association between HHV-8 seropositivity and either the number of lifetime sexual partners or HIV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/110\">",
"       110",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study that included adolescents and adults from different regions of Uganda, HHV-8 seropositivity was lower in females than males (adjusted odds ratio 0.82, 95% CI 0.69-0.97) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/111\">",
"       111",
"      </a>",
"      ]. The prevalence of seropositivity varied in different geographic regions.",
"     </li>",
"     <li>",
"      A study of families in HHV-8 endemic areas found that concordance for HHV-8 seropositivity was greatest between siblings, followed by mother-child pairs [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/107\">",
"       107",
"      </a>",
"      ]. HHV-8 seropositivity in children was associated with residing with a seropositive parent or residing with another seropositive child &lt;14 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/110\">",
"       110",
"      </a>",
"      ]. These results support the theory that horizontal transmission occurs among close contacts.",
"     </li>",
"     <li>",
"      In a study of adults in Uganda with or without HIV",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      KS, 84 percent were seropositive, and half of the remaining seronegative participants had HHV-8 DNA detected either in blood or at mucosal sites [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/112\">",
"       112",
"      </a>",
"      ]. Infection prevalence did not differ by HIV status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Asia",
"    </span>",
"    &nbsp;&mdash;&nbsp;It was presumed that the prevalence of HHV-8 infection was low in Asia since KS is infrequently reported among HIV-infected Asian patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/115\">",
"     115",
"    </a>",
"    ]. However, a study of 174 blood donors in Taiwan found a seroprevalence of 23 percent, and the prevalence in northern Thailand is approximately 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/116,117\">",
"     116,117",
"    </a>",
"    ]. High risk groups have also been identified in China, where approximately 30 percent of patients with serologic evidence of hepatitis B were also HHV-8 seropositive [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/118\">",
"     118",
"    </a>",
"    ]. Similar to what has been observed in Uganda, seroprevalence increased with age until middle adulthood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     South America",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reported rates of HHV-8 infection in urban areas have been as high as 16 percent in healthy study participants, and increases steadily with age [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/119\">",
"     119",
"    </a>",
"    ]. As in Africa, there is evidence for seroconcordance among mothers and children and among siblings [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/107\">",
"     107",
"    </a>",
"    ]. In some areas of South America, such as Peru, the prevalence of HHV-8 infection appears to be elevated in groups of men who have sex with men, and thus the epidemiology of the virus may mimic what is seen in the United States and Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HHV-8 infection has also been noted among tribes that had no contact with outsiders prior to meeting the study investigators. In one such seroepidemiologic study, Brazilian Amerindians had an HHV-8 seroprevalence of over 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact mode(s) of transmission for HHV-8 remains unclear. The search for clues derives from seroepidemiologic studies and from investigations to localize the body sites that harbor the virus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Sexual transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several seroepidemiologic studies suggest that HHV-8 may be sexually transmitted [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/63,100,122-126\">",
"     63,100,122-126",
"    </a>",
"    ]. Evidence for this hypothesis includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In contrast to Epstein-Barr virus (EBV) and cytomegalovirus (CMV), HHV-8 is infrequently detected among children in most areas in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/127\">",
"       127",
"      </a>",
"      ]. Among infants 6 to 38 months of age, 6 percent were infected with HHV-8 compared with 45 percent with EBV [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/122\">",
"       122",
"      </a>",
"      ]. However, HHV-8 seroprevalence as high as 25 percent has been reported in children in South Texas, most of whom were Latino [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/123\">",
"       123",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among MSM, a history of other sexually transmitted diseases (STDs) and a higher number of prior sex partners has been associated with seropositivity to HHV-8 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/64\">",
"       64",
"      </a>",
"      ]. In addition, prevalent HHV-8 infection has been associated with antibodies to hepatitis A, hepatitis B, HSV-2, and a history of more than four male partners in the previous six months [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/124\">",
"       124",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A higher seroprevalence for HHV-8 has been found in both male and female HIV-seronegative patients attending STD clinics compared with the seroprevalence among blood donors [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among commercial sex workers in Kenya and Nigeria, older age and history of an STD has been associated with HHV-8 seropositivity [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/125,126\">",
"       125,126",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among recent recipients of blood transfusions from HHV-8 seronegative donors in Uganda, incident HHV-8 cases were frequent among adults, possibly related to sexual acquisition [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/114\">",
"       114",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H516095098\">",
"    <span class=\"h2\">",
"     Non-sexual transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The associations discussed above support a sexual mode of transmission, but the following observations outside the United States do not:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children in Africa often become HHV-8 seropositive and develop KS prior to the onset of puberty. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Africa'",
"      </a>",
"      above.) Among almost 1000 individuals in Thailand, HHV-8 seroprevalence in women did not differ according to the HHV-8 status of their husbands [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/117\">",
"       117",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Family clustering of HHV-8 seropositivity has been noted among male and female relatives of patients with KS and among parents and siblings in endemic regions [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/102,107,110,128\">",
"       102,107,110,128",
"      </a>",
"      ]. This pattern of familial aggregation, combined with higher seroprevalence rates with increasing age, supports horizontal transmission between close contacts [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/107\">",
"       107",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Africa'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Epidemiologic and virologic data suggest that HHV-8 may be transmitted through saliva [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/99,129,130\">",
"     99,129,130",
"    </a>",
"    ]. Salivary spread could explain both the sexual and horizontal transmission of HHV-8. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Saliva'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Blood transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-8 transmission through blood transfusion was evaluated in Uganda, where HHV-8 is endemic [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/114\">",
"     114",
"    </a>",
"    ]. Of 1811 transfusion recipients who were enrolled, 991 were HHV-8 seronegative and completed two months of follow-up. The risk of seroconversion was significantly higher among recipients of HHV-8 seropositive blood than among recipients of seronegative blood. The excess risk of HHV-8 acquisition from blood transfusion in an endemic area was estimated to be 2.8 percent. In a follow-up study of the same population, receipt of HHV-8-seropositive blood was also associated with an increased risk of death within the few months following transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/131\">",
"     131",
"    </a>",
"    ]. However, the study did not evaluate the specific cause of death in these patients and could not confirm HHV-8 infection among the patients who died.",
"   </p>",
"   <p>",
"    Furthermore, it is important to note that blood products in Uganda are not leukoreduced, and since viremia in HHV-8 infected patients is relatively unusual, extrapolation of the risk of HHV-8 transmission from transfusion in other settings is impossible. Studies from the US and Western Europe have not found evidence to support HHV-8 transmission through blood transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/132,133\">",
"     132,133",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Solid organ transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmission of HHV-8 infection from renal transplant donors to recipients has been documented through assessment of serostatus before and after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/134,135\">",
"     134,135",
"    </a>",
"    ]. In one series of 220 renal transplant recipients, the seroprevalence of HHV-8 increased from 6 percent on the day of transplantation to 18 percent at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/134\">",
"     134",
"    </a>",
"    ]. Among six patients who seroconverted, five of the donors were HHV-8 seropositive. In contrast, none of eight patients with a seronegative donor seroconverted. Two patients who developed KS at two years of follow-up were recent seroconverters.",
"   </p>",
"   <p>",
"    More direct evidence has come from molecular epidemiologic studies, which have clearly documented transmission of HHV-8 from the donor to the recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/136,137\">",
"     136,137",
"    </a>",
"    ]. In one report, seroconversion and viremia coincided with fulminant illnesses in two kidney transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/136\">",
"     136",
"    </a>",
"    ], while the other found that donor cells seeded KS tumors in five of eight recipients with transplant-associated KS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/137\">",
"     137",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19192?source=see_link&amp;anchor=H9#H9\">",
"     \"Disease associations of human herpesvirus 8 infection\", section on 'Solid organ transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although transmission of HHV-8 from donor-derived cells is the most well-studied cause of HHV-8-related infections following solid organ transplantation, reactivation of latent HHV-8 infection in the recipient also occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/138-140\">",
"     138-140",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Sites for harboring virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymerase chain reaction (PCR) testing has been utilized to identify the presence of HHV-8 DNA in various locations. However, there are several important limitations to the PCR-based studies conducted thus far:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PCR does not distinguish between latent cell-associated virus and actively replicating infectious virions.",
"     </li>",
"     <li>",
"      Most of the studies have been performed on patients with KS",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      advanced HIV disease who may have unusually large amounts of reactivation or HHV-8 compared to individuals with an intact immune system.",
"     </li>",
"     <li>",
"      Although the virus is tropic for lymphocytes, peripheral blood mononuclear cells (PBMCs) are only sporadically positive by PCR testing. Even in patients with KS, PBMCs are positive in only about 50 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/141\">",
"       141",
"      </a>",
"      ]. Detection of HHV-8 in PBMCs appears to correlate with the degree of immunosuppression and may be predictive of the development of KS in HIV-seropositive individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Keeping these limitations in mind, the following data have been obtained using PCR-based techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Saliva",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to Epstein-Barr virus, HHV-8 is found in saliva, which may serve as a source for viral transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/94,129,142-150\">",
"     94,129,142-150",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HHV-8 can be detected frequently in the oropharynx from HIV-infected patients with KS and is present in the form of intact virions [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/143-146\">",
"       143-146",
"      </a>",
"      ]. In a study of 196 HIV-infected MSM without KS, viral shedding in saliva was associated with HHV-8 seroconversion, lack of antiretroviral treatment, oral inflammation, and CD4 counts greater than 200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 50 HHV-8 infected MSM who had no clinical evidence of KS, HHV-8 was detected in the saliva in 39 percent of subjects on more than 35 percent of the days on which samples were obtained [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/129\">",
"       129",
"      </a>",
"      ]. In comparison, only 1 percent of anal or genital specimens were positive by PCR. The log titer of HHV-8 in the oral cavity was approximately 2.5 times higher than the titer at other sites.",
"     </li>",
"     <li>",
"      Similar findings were noted in another report of patients with KS in whom HHV-8 was detected in saliva in 37 percent and in semen in 12 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/146\">",
"       146",
"      </a>",
"      ]. The average number of HHV-8 copies per microgram of positive target DNA was much higher in saliva than in semen or plasma (33,000 versus 300 and 40, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Salivary shedding of HHV-8 is not limited to the immunocompromised host in the US. With intensive daily sampling of saliva for HHV-8 DNA, 61 percent of 44 men who have sex with men in Seattle had HHV-8 detected on at least one day [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/151\">",
"     151",
"    </a>",
"    ]. HHV-8 salivary shedding is also common among persons with endemic infection. Approximately one-third of commercial sex workers in Kenya [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/148\">",
"     148",
"    </a>",
"    ] and one-fourth of mothers of children with sickle cell disease in Uganda [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/149\">",
"     149",
"    </a>",
"    ] had HHV-8 DNA in saliva.",
"   </p>",
"   <p>",
"    Based upon these and other observations, saliva appears to be a source of infectious virus. It has been proposed that saliva may be the main mode of HHV-8 transmission in children and that it could be a source of mother-to-child transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/142,147\">",
"     142,147",
"    </a>",
"    ]. Safer sexual practices would not be expected to protect against this mode of transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Semen",
"    </span>",
"    &nbsp;&mdash;&nbsp;An initial report suggested frequent detection of HHV-8 DNA in semen in immunocompetent hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/152\">",
"     152",
"    </a>",
"    ]. However, follow-up studies have suggested that shedding of virus in semen in such patients is relatively infrequent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/153-157\">",
"     153-157",
"    </a>",
"    ]. Even when virus the shed, the number of copies of HHV-8 is much lower than in saliva [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/146\">",
"     146",
"    </a>",
"    ]. The frequency with which HHV-8 is detected in semen may be greater in HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/157,158\">",
"     157,158",
"    </a>",
"    ], although the data are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/154,155\">",
"     154,155",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, while it seems that some HHV-8 infected patients will occasionally have detectable virus in their semen, it is unclear whether this occurs frequently or in sufficient quantities to account for a sexual route of transmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Prostate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varying levels of HHV-8 DNA in prostatic tissue have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/156,159,160\">",
"     156,159,160",
"    </a>",
"    ]. Most reports show the rates to be highest among persons with KS. In an autopsy study of 13 AIDS patients (seven with KS and six without), PCR was positive in the prostate from all five KS patients who had prostate samples obtained and in none of the patients without KS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/161\">",
"     161",
"    </a>",
"    ]. These findings were confirmed in another small study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/162\">",
"     162",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, it is possible that the prostate may serve as a reservoir for HHV-8, with intermittent shedding into the seminal fluid. The importance of these findings for viral transmission remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Female genitourinary tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low rates of HHV-8 DNA detection have been reported in cervicovaginal secretions. One study found DNA in only 1 of 30 cervicovaginal washes from HIV-positive women [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/163\">",
"     163",
"    </a>",
"    ], and another study found HHV-8 DNA in up to 7 percent of cervical or vaginal swabs from HIV-infected Kenyan women [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/148\">",
"     148",
"    </a>",
"    ]. The incidence may be higher in HIV-infected women who also have underlying KS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/112,164\">",
"     112,164",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Gastrointestinal tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-8 shedding is rare in the gastrointestinal tract. In a review of HHV-8 seropositive MSM, HHV-8 was identified in only 16 of 1183 anal swabs (1.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Breast milk",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-8 acquisition in areas where KS is endemic, frequently occurs among infants, prompting studies examining the frequency of HHV-8 detection in breast milk. In both Zambia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/165\">",
"     165",
"    </a>",
"    ] and South Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?29/27/30138/abstract/147\">",
"     147",
"    </a>",
"    ], HHV-8 DNA was detected in breast milk, but the significance of these findings remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606359\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Kaposi's sarcoma, an unusual skin tumor localized in the lower extremities of elderly Mediterranean or Ashkenazi Jewish men, was first described in 1872 by the pathologist Moritz Kaposi. This malignancy was relatively rare until the early 1980s when, with the onset of the HIV epidemic, it was described in several homosexual men in North America. The epidemiology of Kaposi's sarcoma (KS) suggested a link between the development of disease and a transmissible agent. In 1994, a novel gamma herpesvirus was identified in KS biopsies. After sequence analysis of the genome and characterization of the viral replication cycle, this virus was subsequently named human herpesvirus 8 (HHV-8) or Kaposi's sarcoma-associated herpesvirus (KSHV). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HHV-8 fits most closely into the family of human gamma herpesviruses, which includes Epstein-Barr virus. Gamma herpesviruses play an important role in cellular proliferation and the development of malignancies. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Virology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HHV-8 infects a wide variety of cell types, including B cells, endothelial cells, macrophages, and epithelial cells. This broad cellular tropism may be due to the interaction between HHV-8 and a ubiquitous host cell-surface molecule. The highly conserved envelope glycoprotein B (gB) of HHV-8 binds to heparan sulfate-like molecules in cellular targets to initiate adhesion. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Viral entry into host cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of putative cellular receptors for HHV-8 have been defined, including integrin alpha3beta1, DC-SIGN, and the transmembrane light chain of the human",
"      <span class=\"nowrap\">",
"       cystine/glutamate",
"      </span>",
"      exchange transporter system x-c (xCT). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Viral entry into host cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As with all herpesviruses, the HHV-8 replication cycle includes both latent and lytic phases. In studies of transformed cell lines, latent virus can be \"induced\" to upregulate viral replication and expression. In the lytic phase, the virus produces a wide range of structural and replicative gene products that lead to the production of intact virions. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Lytic replication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical observations suggest that T-cells play an important role in the control of KS, as evidenced by the increased incidence of KS among transplant recipients and AIDS patients, the regression of KS with the reduction of immunosuppressive treatment following transplant, and clinical improvement of KS in subjects with immune reconstitution following antiretroviral therapy. Additional evidence also supports a role for natural killer (NK) cells and neutralizing antibodies in control of KS. (See",
"      <a class=\"local\" href=\"#H458573284\">",
"       'Host immune response and control of HHV-8 infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HHV-8 has evolved a number of mechanisms by which it may subvert the host immune system. These factors may help explain why the virus is persistent and widespread in many populations. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Evasion of the host immune response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HHV-8 seroprevalence is relatively high in certain regions, such as Sardinia and Africa, compared with North America and northern Europe, where seroprevalence is low. Besides having different prevalence rates in different geographic regions, the specific risk groups for seropositivity appear to vary depending upon the location. &nbsp;(See",
"      <a class=\"local\" href=\"#H13\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The exact mode(s) of transmission for HHV-8 remains unclear. The search for clues derives from seroepidemiologic studies and from investigations to localize the body sites that harbor the virus. Saliva appears to be a source of infectious virus. It has been proposed that saliva may be the main mode of HHV-8 transmission in children and that it could be a source of mother-to-child transmission. Other possible modes of transmission include sexual transmission, blood transfusions, and solid organ transplantation. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/1\">",
"      Braun M. Classics in Oncology. Idiopathic multiple pigmented sarcoma of the skin by Kaposi. CA Cancer J Clin 1982; 32:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/2\">",
"      Hymes KB, Cheung T, Greene JB, et al. Kaposi's sarcoma in homosexual men-a report of eight cases. Lancet 1981; 2:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/3\">",
"      Centers for Disease Control (CDC). Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men--New York City and California. MMWR Morb Mortal Wkly Rep 1981; 30:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/4\">",
"      Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/5\">",
"      Iscovich J, Boffetta P, Winkelmann R, et al. Classic Kaposi's sarcoma in Jews living in Israel, 1961-1989: a population-based incidence study. AIDS 1998; 12:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/6\">",
"      Fenig E, Brenner B, Rakowsky E, et al. Classic Kaposi sarcoma: experience at Rabin Medical Center in Israel. Am J Clin Oncol 1998; 21:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/7\">",
"      Cook-Mozaffari P, Newton R, Beral V, Burkitt DP. The geographical distribution of Kaposi's sarcoma and of lymphomas in Africa before the AIDS epidemic. Br J Cancer 1998; 78:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/8\">",
"      Olsen SJ, Chang Y, Moore PS, et al. Increasing Kaposi's sarcoma-associated herpesvirus seroprevalence with age in a highly Kaposi's sarcoma endemic region, Zambia in 1985. AIDS 1998; 12:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/9\">",
"      Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990; 335:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/10\">",
"      Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med 2000; 342:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/11\">",
"      Akula SM, Pramod NP, Wang FZ, Chandran B. Integrin alpha3beta1 (CD 49c/29) is a cellular receptor for Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) entry into the target cells. Cell 2002; 108:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/12\">",
"      Hassman LM, Ellison TJ, Kedes DH. KSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation. J Clin Invest 2011; 121:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/13\">",
"      Akula SM, Pramod NP, Wang FZ, Chandran B. Human herpesvirus 8 envelope-associated glycoprotein B interacts with heparan sulfate-like moieties. Virology 2001; 284:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/14\">",
"      Rappocciolo G, Jenkins FJ, Hensler HR, et al. DC-SIGN is a receptor for human herpesvirus 8 on dendritic cells and macrophages. J Immunol 2006; 176:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/15\">",
"      Kaleeba JA, Berger EA. Kaposi's sarcoma-associated herpesvirus fusion-entry receptor: cystine transporter xCT. Science 2006; 311:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/16\">",
"      Paulose-Murphy M, Ha NK, Xiang C, et al. Transcription program of human herpesvirus 8 (kaposi's sarcoma-associated herpesvirus). J Virol 2001; 75:4843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/17\">",
"      Cesarman E, Moore PS, Rao PH, et al. In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood 1995; 86:2708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/18\">",
"      Sun R, Lin SF, Gradoville L, et al. A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A 1998; 95:10866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/19\">",
"      Mercader M, Taddeo B, Panella JR, et al. Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells. Am J Pathol 2000; 156:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/20\">",
"      Chang J, Renne R, Dittmer D, Ganem D. Inflammatory cytokines and the reactivation of Kaposi's sarcoma-associated herpesvirus lytic replication. Virology 2000; 266:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/21\">",
"      Davis DA, Rinderknecht AS, Zoeteweij JP, et al. Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood 2001; 97:3244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/22\">",
"      Zhu FX, King SM, Smith EJ, et al. A Kaposi's sarcoma-associated herpesviral protein inhibits virus-mediated induction of type I interferon by blocking IRF-7 phosphorylation and nuclear accumulation. Proc Natl Acad Sci U S A 2002; 99:5573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/23\">",
"      Bellare P, Ganem D. Regulation of KSHV lytic switch protein expression by a virus-encoded microRNA: an evolutionary adaptation that fine-tunes lytic reactivation. Cell Host Microbe 2009; 6:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/24\">",
"      Lei X, Bai Z, Ye F, et al. Regulation of NF-kappaB inhibitor IkappaBalpha and viral replication by a KSHV microRNA. Nat Cell Biol 2010; 12:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/25\">",
"      G&uuml;nther T, Grundhoff A. The epigenetic landscape of latent Kaposi sarcoma-associated herpesvirus genomes. PLoS Pathog 2010; 6:e1000935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/26\">",
"      Toth Z, Maglinte DT, Lee SH, et al. Epigenetic analysis of KSHV latent and lytic genomes. PLoS Pathog 2010; 6:e1001013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/27\">",
"      Gregory SM, West JA, Dillon PJ, et al. Toll-like receptor signaling controls reactivation of KSHV from latency. Proc Natl Acad Sci U S A 2009; 106:11725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/28\">",
"      Beral V. The epidemiology of cancer in AIDS patients. AIDS 1991; 5 Suppl 2:S99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/29\">",
"      Wijnveen AC, Persson H, Bj&ouml;rck S, Blohm&eacute; I. Disseminated Kaposi's sarcoma--full regression after withdrawal of immunosuppressive therapy: report of a case. Transplant Proc 1987; 19:3735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/30\">",
"      Nagy S, Gyulai R, Kemeny L, et al. Iatrogenic Kaposi's sarcoma: HHV8 positivity persists but the tumors regress almost completely without immunosuppressive therapy. Transplantation 2000; 69:2230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/31\">",
"      Cattelan AM, Calabr&ograve; ML, Gasperini P, et al. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J Natl Cancer Inst Monogr 2001; :44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/32\">",
"      Paparizos VA, Kyriakis KP, Papastamopoulos V, et al. Response of AIDS-associated Kaposi sarcoma to highly active antiretroviral therapy alone. J Acquir Immune Defic Syndr 2002; 30:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/33\">",
"      Guihot A, Dupin N, Marcelin AG, et al. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. J Infect Dis 2006; 194:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/34\">",
"      Wilkinson J, Cope A, Gill J, et al. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy. J Virol 2002; 76:2634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/35\">",
"      Lambert M, Gannag&eacute; M, Karras A, et al. Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma. Blood 2006; 108:3871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/36\">",
"      Bihl F, Mosam A, Henry LN, et al. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma. AIDS 2007; 21:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/37\">",
"      Bihl F, Berger C, Chisholm JV 3rd, et al. Cellular immune responses and disease control in acute AIDS-associated Kaposi's sarcoma. AIDS 2009; 23:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/38\">",
"      Biggar RJ, Chaturvedi AK, Goedert JJ, et al. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007; 99:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/39\">",
"      Sirianni MC, Vincenzi L, Topino S, et al. NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. Eur J Immunol 2002; 32:2711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/40\">",
"      Kimball LE, Casper C, Koelle DM, et al. Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma. J Infect Dis 2004; 189:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/41\">",
"      Lagos D, Vart RJ, Gratrix F, et al. Toll-like receptor 4 mediates innate immunity to Kaposi sarcoma herpesvirus. Cell Host Microbe 2008; 4:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/42\">",
"      West J, Damania B. Upregulation of the TLR3 pathway by Kaposi's sarcoma-associated herpesvirus during primary infection. J Virol 2008; 82:5440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/43\">",
"      Weber KS, Gr&ouml;ne HJ, R&ouml;cken M, et al. Selective recruitment of Th2-type cells and evasion from a cytotoxic immune response mediated by viral macrophage inhibitory protein-II. Eur J Immunol 2001; 31:2458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/44\">",
"      Brander C, Suscovich T, Lee Y, et al. Impaired CTL recognition of cells latently infected with Kaposi's sarcoma-associated herpes virus. J Immunol 2000; 165:2077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/45\">",
"      Ishido S, Wang C, Lee BS, et al. Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J Virol 2000; 74:5300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/46\">",
"      Coscoy L, Ganem D. A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation. J Clin Invest 2001; 107:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/47\">",
"      Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/48\">",
"      Bertin J, Armstrong RC, Ottilie S, et al. Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis. Proc Natl Acad Sci U S A 1997; 94:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/49\">",
"      Djerbi M, Screpanti V, Catrina AI, et al. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med 1999; 190:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/50\">",
"      Flore O, Rafii S, Ely S, et al. Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus. Nature 1998; 394:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/51\">",
"      Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med 2000; 6:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/52\">",
"      Lundquist A, Barr&eacute; B, Bienvenu F, et al. Kaposi sarcoma-associated viral cyclin K overrides cell growth inhibition mediated by oncostatin M through STAT3 inhibition. Blood 2003; 101:4070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/53\">",
"      Seo T, Park J, Lee D, et al. Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus binds to p53 and represses p53-dependent transcription and apoptosis. J Virol 2001; 75:6193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/54\">",
"      Nakamura H, Li M, Zarycki J, Jung JU. Inhibition of p53 tumor suppressor by viral interferon regulatory factor. J Virol 2001; 75:7572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/55\">",
"      Chatterjee M, Osborne J, Bestetti G, et al. Viral IL-6-induced cell proliferation and immune evasion of interferon activity. Science 2002; 298:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/56\">",
"      Pati S, Cavrois M, Guo HG, et al. Activation of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi's sarcoma pathogenesis. J Virol 2001; 75:8660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/57\">",
"      Schwarz M, Murphy PM. Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor constitutively activates NF-kappa B and induces proinflammatory cytokine and chemokine production via a C-terminal signaling determinant. J Immunol 2001; 167:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/58\">",
"      Bais C, Santomasso B, Coso O, et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 1998; 391:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/59\">",
"      Hong YK, Foreman K, Shin JW, et al. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet 2004; 36:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/60\">",
"      Wang HW, Trotter MW, Lagos D, et al. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 2004; 36:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/61\">",
"      Renne R, Lagunoff M, Zhong W, Ganem D. The size and conformation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions. J Virol 1996; 70:8151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/62\">",
"      Ballestas ME, Chatis PA, Kaye KM. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 1999; 284:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/63\">",
"      Simpson GR, Schulz TF, Whitby D, et al. Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet 1996; 348:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/64\">",
"      Martin JN, Ganem DE, Osmond DH, et al. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998; 338:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/65\">",
"      Kedes DH, Operskalski E, Busch M, et al. The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med 1996; 2:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/66\">",
"      Pollack MS, Safai B, Myskowski PL, et al. Frequencies of HLA and Gm immunogenetic markers in Kaposi's sarcoma. Tissue Antigens 1983; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/67\">",
"      Contu L, Cerimele D, Pintus A, et al. HLA and Kaposi's sarcoma in Sardinia. Tissue Antigens 1984; 23:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/68\">",
"      Kaloterakis A, Papasteriades C, Filiotou A, et al. HLA in familial and nonfamilial Mediterranean Kaposi's sarcoma in Greece. Tissue Antigens 1995; 45:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/69\">",
"      Ioannidis JP, Skolnik PR, Chalmers TC, Lau J. Human leukocyte antigen associations of epidemic Kaposi's sarcoma. AIDS 1995; 9:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/70\">",
"      Tzfoni EE, Scherman L, Battat S, Brautbar H. No HLA antigen is significant in classic Kaposi's sarcoma. J Am Acad Dermatol 1993; 28:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/71\">",
"      Strichman-Almashanu L, Weltfriend S, Gideoni O, et al. No significant association between HLA antigens and classic Kaposi sarcoma: molecular analysis of 49 Jewish patients. J Clin Immunol 1995; 15:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/72\">",
"      Melbye M, Kestens L, Biggar RJ, et al. HLA studies of endemic African Kaposi's sarcoma patients and matched controls: no association with HLA-DR5. Int J Cancer 1987; 39:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/73\">",
"      Marmor M, Winchester R, Zeleniuch-Jacquotte A, et al. Evidence for an effect of human leukocyte antigens on susceptibility to Kaposi's sarcoma related to charge and peptide-binding properties of class I molecules. AIDS 1995; 9:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/74\">",
"      Gay&agrave; A, Esteve A, Casabona J, et al. Amino acid residue at position 13 in HLA-DR beta chain plays a critical role in the development of Kaposi's sarcoma in AIDS patients. AIDS 2004; 18:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/75\">",
"      Aoki Y, Jones KD, Tosato G. Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. J Hematother Stem Cell Res 2000; 9:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/76\">",
"      Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/77\">",
"      Foster CB, Lehrnbecher T, Samuels S, et al. An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. Blood 2000; 96:2562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/78\">",
"      Gazouli M, Zavos G, Papaconstantinou I, et al. The interleukin-6-174 promoter polymorphism is associated with a risk of development of Kaposi's sarcoma in renal transplant recipients. Anticancer Res 2004; 24:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/79\">",
"      Guttman-Yassky E, Cohen A, Kra-Oz Z, et al. Familial clustering of classic Kaposi sarcoma. J Infect Dis 2004; 189:2023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/80\">",
"      Brown EE, Fallin D, Ruczinski I, et al. Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity. Cancer Epidemiol Biomarkers Prev 2006; 15:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/81\">",
"      Mocroft A, Youle M, Gazzard B, et al. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS 1996; 10:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/82\">",
"      Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 1999; 340:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/83\">",
"      Whitby D, Howard MR, Tenant-Flowers M, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 1995; 346:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/84\">",
"      Campbell TB, Borok M, Gwanzura L, et al. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage. AIDS 2000; 14:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/85\">",
"      Broccolo F, Bossolasco S, Careddu AM, et al. Detection of DNA of lymphotropic herpesviruses in plasma of human immunodeficiency virus-infected patients: frequency and clinical significance. Clin Diagn Lab Immunol 2002; 9:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/86\">",
"      Gill J, Bourboulia D, Wilkinson J, et al. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr 2002; 31:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/87\">",
"      Lorenzen T, Albrecht D, Paech V, et al. HHV-8 DNA in blood and the development of HIV-associated Kaposi's sarcoma in the era of HAART--a prospective evaluation. Eur J Med Res 2002; 7:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/88\">",
"      Cannon MJ, Dollard SC, Black JB, et al. Risk factors for Kaposi's sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus. AIDS 2003; 17:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/89\">",
"      Grundhoff A, Ganem D. Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest 2004; 113:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/90\">",
"      Sarmati L. Serological testing for human herpesvirus 8. Herpes 2001; 8:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/91\">",
"      Engels EA, Atkinson JO, Graubard BI, et al. Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis 2007; 196:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/92\">",
"      Verbeek W, Frankel M, Miles S, et al. Seroprevalence of HHV-8 antibodies in HIV-positive homosexual men without Kaposi's sarcoma and their clinical follow-up. Am J Clin Pathol 1998; 109:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/93\">",
"      Regamey N, Cathomas G, Schwager M, et al. High human herpesvirus 8 seroprevalence in the homosexual population in Switzerland. J Clin Microbiol 1998; 36:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/94\">",
"      Casper C, Redman M, Huang ML, et al. HIV infection and human herpesvirus-8 oral shedding among men who have sex with men. J Acquir Immune Defic Syndr 2004; 35:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/95\">",
"      Gao SJ, Kingsley L, Li M, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med 1996; 2:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/96\">",
"      Marcelin AG, Dupin N, Bossi P, Calvez V. Seroprevalence of human herpesvirus-8 in healthy subjects and patients with AIDS-associated and classical Kaposi's sarcoma in France. AIDS 1998; 12:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/97\">",
"      Rabkin CS, Schulz TF, Whitby D, et al. Interassay correlation of human herpesvirus 8 serologic tests. HHV-8 Interlaboratory Collaborative Group. J Infect Dis 1998; 178:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/98\">",
"      Kedes DH, Ganem D, Ameli N, et al. The prevalence of serum antibody to human herpesvirus 8 (Kaposi sarcoma-associated herpesvirus) among HIV-seropositive and high-risk HIV-seronegative women. JAMA 1997; 277:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/99\">",
"      Cannon MJ, Dollard SC, Smith DK, et al. Blood-borne and sexual transmission of human herpesvirus 8 in women with or at risk for human immunodeficiency virus infection. N Engl J Med 2001; 344:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/100\">",
"      Casper C, Meier AS, Wald A, et al. Human herpesvirus 8 infection among adolescents in the REACH cohort. Arch Pediatr Adolesc Med 2006; 160:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/101\">",
"      Luppi M, Borozzi P, Morabitio F, et al. HHV-8 Infection in blood donors and patients with malignant and reactive lymphoproliferations from different regions of Italy. Haematologica 1998; 83:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/102\">",
"      Angeloni A, Heston L, Uccini S, et al. High prevalence of antibodies to human herpesvirus 8 in relatives of patients with classic Kaposi's sarcoma from Sardinia. J Infect Dis 1998; 177:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/103\">",
"      Guttman-Yassky E, Kra-Oz Z, Dubnov J, et al. Infection with Kaposi's sarcoma-associated herpesvirus among families of patients with classic Kaposi's sarcoma. Arch Dermatol 2005; 141:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/104\">",
"      Ziegler JL, Templeton AC, Vogel CL. Kaposi's sarcoma: a comparison of classical, endemic, and epidemic forms. Semin Oncol 1984; 11:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/105\">",
"      Bestetti G, Renon G, Maucl&eacute;re P, et al. High seroprevalence of human herpesvirus-8 in pregnant women and prostitutes from Cameroon. AIDS 1998; 12:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/106\">",
"      Mayama S, Cuevas LE, Sheldon J, et al. Prevalence and transmission of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in Ugandan children and adolescents. Int J Cancer 1998; 77:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/107\">",
"      Plancoulaine S, Abel L, van Beveren M, et al. Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population. Lancet 2000; 356:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/108\">",
"      Lennette ET, Blackbourn DJ, Levy JA. Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet 1996; 348:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/109\">",
"      Dollard SC, Butler LM, Jones AM, et al. Substantial regional differences in human herpesvirus 8 seroprevalence in sub-Saharan Africa: insights on the origin of the \"Kaposi's sarcoma belt\". Int J Cancer 2010; 127:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/110\">",
"      Butler LM, Were WA, Balinandi S, et al. Human herpesvirus 8 infection in children and adults in a population-based study in rural Uganda. J Infect Dis 2011; 203:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/111\">",
"      Biryahwaho B, Dollard SC, Pfeiffer RM, et al. Sex and geographic patterns of human herpesvirus 8 infection in a nationally representative populationbased sample in Uganda. J Infect Dis 2010; 202:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/112\">",
"      Johnston C, Orem J, Okuku F, et al. Impact of HIV infection and Kaposi sarcoma on human herpesvirus-8 mucosal replication and dissemination in Uganda. PLoS One 2009; 4:e4222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/113\">",
"      Minhas V, Crabtree KL, Chao A, et al. Early childhood infection by human herpesvirus 8 in Zambia and the role of human immunodeficiency virus type 1 coinfection in a highly endemic area. Am J Epidemiol 2008; 168:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/114\">",
"      Hladik W, Dollard SC, Mermin J, et al. Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med 2006; 355:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/115\">",
"      Sivayathorn A, Srihra B, Leesanguankul W. Prevalence of skin disease in patients infected with human immunodeficiency virus in Bangkok, Thailand. Ann Acad Med Singapore 1995; 24:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/116\">",
"      Wang YF, Lee SB, Cheng LC, et al. Detection of serum antibodies to three different recombinant antigens of human herpesvirus 8 by immunoblotting: seroprevalence studies in Taiwan. Clin Chim Acta 2002; 320:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/117\">",
"      Chen N, Nelson KE, Jenkins FJ, et al. Seroprevalence of human herpesvirus 8 infection in Northern Thailand. Clin Infect Dis 2004; 39:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/118\">",
"      Xie Y, Ruan B, Chen Y, et al. Kaposi's sarcoma-associated herpesvirus infection in Chinese patients with chronic hepatitis B. J Med Virol 2011; 83:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/119\">",
"      Freitas RB, Freitas MR, Linhares AC. Prevalence of human herpesvirus 8 antibodies in the population of Bel&eacute;m, Par&aacute;, Brazil. Rev Inst Med Trop Sao Paulo 2002; 44:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/120\">",
"      Guanira JV, Casper C, Lama JR, et al. Prevalence and correlates of human herpesvirus 8 infection among Peruvian men who have sex with men. J Acquir Immune Defic Syndr 2008; 49:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/121\">",
"      Biggar RJ, Whitby D, Marshall V, et al. Human herpesvirus 8 in Brazilian Amerindians: a hyperendemic population with a new subtype. J Infect Dis 2000; 181:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/122\">",
"      Martro E, Bulterys M, Stewart JA, et al. Comparison of human herpesvirus 8 and Epstein-Barr virus seropositivity among children in areas endemic and non-endemic for Kaposi's sarcoma. J Med Virol 2004; 72:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/123\">",
"      Baillargeon J, Leach CT, Deng JH, et al. High prevalence of human herpesvirus 8 (HHV-8) infection in south Texas children. J Med Virol 2002; 67:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/124\">",
"      Casper C, Wald A, Pauk J, et al. Correlates of prevalent and incident Kaposi's sarcoma-associated herpesvirus infection in men who have sex with men. J Infect Dis 2002; 185:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/125\">",
"      Lavreys L, Chohan B, Ashley R, et al. Human herpesvirus 8: seroprevalence and correlates in prostitutes in Mombasa, Kenya. J Infect Dis 2003; 187:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/126\">",
"      Eltom MA, Mbulaiteye SM, Dada AJ, et al. Transmission of human herpesvirus 8 by sexual activity among adults in Lagos, Nigeria. AIDS 2002; 16:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/127\">",
"      Blauvelt A, Sei S, Cook PM, et al. Human herpesvirus 8 infection occurs following adolescence in the United States. J Infect Dis 1997; 176:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/128\">",
"      Borges JD, Souza VA, Giambartolomei C, et al. Transmission of human herpesvirus type 8 infection within families in american indigenous populations from the Brazilian Amazon. J Infect Dis 2012; 205:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/129\">",
"      Pauk J, Huang ML, Brodie SJ, et al. Mucosal shedding of human herpesvirus 8 in men. N Engl J Med 2000; 343:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/130\">",
"      Sosa C, Benetucci J, Hanna C, et al. Human herpesvirus 8 can be transmitted through blood in drug addicts. Medicina (B Aires) 2001; 61:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/131\">",
"      Hladik W, Pellett PE, Hancock J, et al. Association between transfusion with Human herpesvirus 8 antibody-positive blood and subsequent mortality. J Infect Dis 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/132\">",
"      Cannon MJ, Operskalski EA, Mosley JW, et al. Lack of evidence for human herpesvirus-8 transmission via blood transfusion in a historical US cohort. J Infect Dis 2009; 199:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/133\">",
"      Schennach H, Sch&ouml;nitzer D, Wachter H, Fuchs D. Blood donations and viruses. Lancet 1997; 349:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/134\">",
"      Regamey N, Tamm M, Wernli M, et al. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med 1998; 339:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/135\">",
"      Nocera A, Corbellino M, Valente U, et al. Posttransplant human herpes virus 8 infection and seroconversion in a Kaposi's sarcoma affected kidney recipient transplanted from a human herpes virus 8 positive living related donor. Transplant Proc 1998; 30:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/136\">",
"      Luppi M, Barozzi P, Schulz TF, et al. Bone marrow failure associated with human herpesvirus 8 infection after transplantation. N Engl J Med 2000; 343:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/137\">",
"      Barozzi P, Luppi M, Facchetti F, et al. Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med 2003; 9:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/138\">",
"      Parravicini C, Scalamogna C, Calattini S, et al. KSHV reactivation in post-transplant Kaposi sarcoma. Nat Med 2003; 9:986; author reply 986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/139\">",
"      Parravicini C, Olsen SJ, Capra M, et al. Risk of Kaposi's sarcoma-associated herpes virus transmission from donor allografts among Italian posttransplant Kaposi's sarcoma patients. Blood 1997; 90:2826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/140\">",
"      Farge D, Lebb&eacute; C, Marjanovic Z, et al. Human herpes virus-8 and other risk factors for Kaposi's sarcoma in kidney transplant recipients. Groupe Cooperatif de Transplantation d' Ile de France (GCIF). Transplantation 1999; 67:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/141\">",
"      Moore PS, Kingsley LA, Holmberg SD, et al. Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma. AIDS 1996; 10:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/142\">",
"      Andreoni M, Sarmati L, Nicastri E, et al. Primary human herpesvirus 8 infection in immunocompetent children. JAMA 2002; 287:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/143\">",
"      Koelle DM, Huang ML, Chandran B, et al. Frequent detection of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in saliva of human immunodeficiency virus-infected men: clinical and immunologic correlates. J Infect Dis 1997; 176:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/144\">",
"      Vieira J, Huang ML, Koelle DM, Corey L. Transmissible Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in saliva of men with a history of Kaposi's sarcoma. J Virol 1997; 71:7083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/145\">",
"      Blackbourn DJ, Lennette ET, Ambroziak J, et al. Human herpesvirus 8 detection in nasal secretions and saliva. J Infect Dis 1998; 177:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/146\">",
"      LaDuca JR, Love JL, Abbott LZ, et al. Detection of human herpesvirus 8 DNA sequences in tissues and bodily fluids. J Infect Dis 1998; 178:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/147\">",
"      Dedicoat M, Newton R, Alkharsah KR, et al. Mother-to-child transmission of human herpesvirus-8 in South Africa. J Infect Dis 2004; 190:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/148\">",
"      Taylor MM, Chohan B, Lavreys L, et al. Shedding of human herpesvirus 8 in oral and genital secretions from HIV-1-seropositive and -seronegative Kenyan women. J Infect Dis 2004; 190:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/149\">",
"      Mbulaiteye SM, Pfeiffer RM, Engels EA, et al. Detection of kaposi sarcoma-associated herpesvirus DNA in saliva and buffy-coat samples from children with sickle cell disease in Uganda. J Infect Dis 2004; 190:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/150\">",
"      de Souza VA, Sumita LM, Nascimento MC, et al. Human herpesvirus-8 infection and oral shedding in Amerindian and non-Amerindian populations in the Brazilian Amazon region. J Infect Dis 2007; 196:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/151\">",
"      Casper C, Krantz E, Selke S, et al. Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men. J Infect Dis 2007; 195:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/152\">",
"      Monini P, de Lellis L, Fabris M, et al. Kaposi's sarcoma-associated herpesvirus DNA sequences in prostate tissue and human semen. N Engl J Med 1996; 334:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/153\">",
"      Pellett PE, Spira TJ, Bagasra O, et al. Multicenter comparison of PCR assays for detection of human herpesvirus 8 DNA in semen. J Clin Microbiol 1999; 37:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/154\">",
"      Ambroziak JA, Blackbourn DJ, Herndier BG, et al. Herpes-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients. Science 1995; 268:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/155\">",
"      Diamond C, Huang ML, Kedes DH, et al. Absence of detectable human herpesvirus 8 in the semen of human immunodeficiency virus-infected men without Kaposi's sarcoma. J Infect Dis 1997; 176:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/156\">",
"      Tasaka T, Said JW, Morosetti R, et al. Is Kaposi's sarcoma--associated herpesvirus ubiquitous in urogenital and prostate tissues? Blood 1997; 89:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/157\">",
"      Huang YQ, Li JJ, Poiesz BJ, et al. Detection of the herpesvirus-like DNA sequences in matched specimens of semen and blood from patients with AIDS-related Kaposi's sarcoma by polymerase chain reaction in situ hybridization. Am J Pathol 1997; 150:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/158\">",
"      Howard MR, Whitby D, Bahadur G, et al. Detection of human herpesvirus 8 DNA in semen from HIV-infected individuals but not healthy semen donors. AIDS 1997; 11:F15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/159\">",
"      Rubin MA, Parry JP, Singh B. Kaposi's sarcoma associated herpesvirus deoxyribonucleic acid sequences: lack of detection in prostatic tissue of human immunodeficiency virus-negative immunocompetent adults. J Urol 1998; 159:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/160\">",
"      Lebb&eacute; C, Pellet C, Tatoud R, et al. Absence of human herpesvirus 8 sequences in prostate specimens. AIDS 1997; 11:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/161\">",
"      Corbellino M, Poirel L, Bestetti G, et al. Restricted tissue distribution of extralesional Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS patients with Kaposi's sarcoma. AIDS Res Hum Retroviruses 1996; 12:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/162\">",
"      Diamond C, Brodie SJ, Krieger JN, et al. Human herpesvirus 8 in the prostate glands of men with Kaposi's sarcoma. J Virol 1998; 72:6223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/163\">",
"      Calabr&ograve; ML, Fiore JR, Favero A, et al. Detection of human herpesvirus 8 in cervicovaginal secretions and seroprevalence in human immunodeficiency virus type 1-seropositive and -seronegative women. J Infect Dis 1999; 179:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/164\">",
"      Lampinen TM, Kulasingam S, Min J, et al. Detection of Kaposi's sarcoma-associated herpesvirus in oral and genital secretions of Zimbabwean women. J Infect Dis 2000; 181:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/27/30138/abstract/165\">",
"      Brayfield BP, Phiri S, Kankasa C, et al. Postnatal human herpesvirus 8 and human immunodeficiency virus type 1 infection in mothers and infants from Zambia. J Infect Dis 2003; 187:559.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8277 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-ECB61E16A9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_27_30138=[""].join("\n");
var outline_f29_27_30138=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H606359\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VIROLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Viral entry into host cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Lytic replication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H458573284\">",
"      Host immune response and control of HHV-8 infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Evasion of the host immune response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Control of the cell cycle and oncogenic transformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Risk factors for disease progression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - HLA background",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Immunomodulating genes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Replicating virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Latent HHV-8 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      North America and northern Europe",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Mediterranean",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Africa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Asia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      South America",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Sexual transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H516095098\">",
"      Non-sexual transmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Sites for harboring virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Saliva",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Semen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Prostate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Female genitourinary tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Breast milk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H606359\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6743?source=related_link\">",
"      Diagnosis and antiviral therapy of human herpesvirus 8 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19192?source=related_link\">",
"      Disease associations of human herpesvirus 8 infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_27_30139="Historical classification of CMD";
var content_f29_27_30139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Historical classification of congenital muscular dystrophy (CMD)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Classic CMD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Merosin deficient CMD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Primary merosin deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Secondary merosin deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Merosin positive CMD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Classic CMD without distinguishing features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Rigid spine syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        CMD with distal hyperextensibility (Ullrich type)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        CMD with mental retardation or sensory abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        CMD with central nervous system (CNS) abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fukuyama CMD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Muscle-eye-brain disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Walker-Warburg syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jones, K, North, K. The congenital muscular dystrophies. In: Neuromuscular Disorders of infancy, Childhood, and Adolescence: A Clinician's Approach, Jones, HR, De Vivo, DC, Darras, BT (Eds). Butterworth Heinemann, Philadelphia 2003. p.633. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_27_30139=[""].join("\n");
var outline_f29_27_30139=null;
var title_f29_27_30140="NHL treatment response criteria";
var content_f29_27_30140=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F64921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F64921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    International Workshop Criteria (IWC) for assessing response to treatment in non-Hodgkin lymphoma (NHL)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Complete remission (CR)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No clinical evidence of disease or disease-related symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         &bull; Typically FDG-avid lymphomas: a post-treatment residual mass of any size is permitted as long as it is PET negative.",
"        </p>",
"        <p>",
"         &bull; Variably FDG-avid lymphoma/FDG avidity unknown: all lymph nodes normal size by CT.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spleen and liver non-palpable and without nodules.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If pretreatment bone marrow biopsy was positive, repeat bone marrow biopsy must be negative; if morphologically indeterminate, immunohistochemistry should be negative.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Partial remission (PR)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Regression of measurable disease with at least 50 percent decrease in nodal size as determined by SPD.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For a typically FDG-avid lymphoma, the post-treatment PET should be positive in at least one previously involved site.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No increase in the size of other nodes, liver, or spleen.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Regression of splenic or hepatic nodules by at least 50 percent as determined by the SPD.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No new sites of disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Stable disease (SD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Failure to attain CR/PR or PD.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For typically FDG-avid lymphomas, the post-treatment PET should be positive at prior sites of disease and no new sites should be present on PET or CT.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Relapse after CR or Progressive disease (PD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Appearance of any new lesion more than 1.5 cm in long axis. If long axis is 1.1 to 1.5 cm, it should only be considered abnormal if its short axis is more than 1.0 cm.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50 percent increase in the longest diameter of a previously identified node more than 1 cm in short axis or in the SPD of more than one node.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lesions &gt;1.5 cm should be PET positive in typical FDG-avid lymphoma or if PET positive before therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increasing FDG uptake in a previously unaffected site should only be considered relapse or PD after confirmation with other modalities.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        New or recurrent involvement of the bone marrow.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Typically FDG-avid lymphomas include: diffuse large B cell lymphoma, Hodgkin lymphoma, follicular lymphoma, and mantle cell lymphoma. Variably FDG-avid lymphomas include all other non-Hodgkin lymphomas.",
"    <div class=\"footnotes\">",
"     SPD: sum of the product of the diameters.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Cheson BD, Pfistner B, Juweid ME, et al. Revised criteria for malignant lymphoma. J Clin Oncol 2007; 25:579.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_27_30140=[""].join("\n");
var outline_f29_27_30140=null;
var title_f29_27_30141="ACP Best Practice Advice - Lower back pain";
var content_f29_27_30141=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American College of Physicians best practice advice: Diagnostic imaging for low back pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Diagnostic imaging techniques",
"       </td>",
"       <td>",
"        Radiography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Computed tomography (CT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Magnetic resonance imaging (MRI)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Indications for diagnostic imaging",
"       </td>",
"       <td>",
"        <p>",
"         Radiography is recommended in patients with acute low back pain who have major risk factors for cancer (new onset of low back pain with history of cancer, multiple risk factors for cancer, or strong clinical suspicion for cancer).",
"        </p>",
"        <p>",
"         MRI is recommended in patients with acute low back pain who have risk factors for spinal infection (new onset of low back pain with fever and history of intravenous drug use or recent infection), risk factors for or signs of the cauda equina syndrome (new urinary retention, fecal incontinence, or saddle anesthesia), or severe or progressive neurologic deficits.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Radiography is recommended after a trial of therapy in patients with minor risk factors for cancer (unexplained weight loss or age &gt;50 years), risk factors for ankylosing spondylitis (morning stiffness that improves with exercise, alternating buttock pain, awakening because of back pain during the second part of the night), risk factors for vertebral compression fracture [history of osteoporosis, glucocorticoid use, significant trauma, or older age (&gt;65 years for men or &gt;75 years for women)].",
"        </p>",
"        <p>",
"         MRI is recommended after a trial of therapy in patients with signs/symptoms of radiculopathy (back pain with leg pain in an L4, L5, or S1 nerve root distribution or positive result on straight leg raise or crossed straight leg raise test) who are candidates for surgery or epidural steroid injection. MRI is also recommended in patients with risk factors for or symptoms of symptomatic spinal stenosis (radiating leg pain, older age, or pseudoclaudication) in patients who are candidates for surgery.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MRI is generally preferred over CT scan for most cases of low back pain. CT scan may help visualize bony abnormalities and is used when patients have a magnetic implant that is not suitable for MRI.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Repeated imaging is only recommended in patients with new or changed low back symptoms.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Evidence that expanding imaging to patients without these indications does not improve outcomes",
"       </td>",
"       <td>",
"        Randomized trials of routine imaging versus usual care without routine imaging in patients without indications for diagnostic imaging suggest no clinically meaningful benefits on outcomes related to pain, function, quality of life, or mental health.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other supporting evidence includes the weak correlation between most imaging findings and symptoms, the favorable natural history of acute low back pain with or without imaging, the low prevalence of serious or specific underlying conditions, and unclear effects of imaging on treatment decisions.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Harms of unnecessary imaging",
"       </td>",
"       <td>",
"        Radiation exposure (for lumbar radiography and CT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Labeling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypersensitivity reactions and contrast nephropathy (for iodinated contrast with CT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potential association with subsequent unnecessary, invasive, and expensive procedures",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Approaches to overcome barriers to evidence-based practice",
"       </td>",
"       <td>",
"        Patient expectations or preferences for routine imaging: Use talking points based on evidence-based guidelines to aid in patient education",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Time constraints: Use evidence-based online or print education material to supplement face-to-face education",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clinician uncertainty: Recognize the low likelihood of serious conditions in the absence of clinical risk factors and the evidence that shows no benefit associated with routine imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clinician incentives based on patient satisfaction: Advocate for incentives that are based on providing appropriate care",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"7\">",
"        Talking points for clinicians when discussing low back pain imaging with patients",
"       </td>",
"       <td>",
"        Risk factor assessment can almost always identify patients who require imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The prevalence of serious underlying conditions is low in patients without risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The natural history of acute low back pain is quite favorable, but patients require reevaluation if they are not better after about 1 month",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Routine imaging does not improve clinical outcomes but increases costs and may lead to potentially unnecessary invasive treatments, such as surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imaging abnormalities are extremely common, especially in older adults, but most are poorly correlated with symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In most cases, treatment plans do not change after imaging studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Back imaging is associated with radiation exposure, which can increase the risk for cancer in the case of lumbar radiography and computed tomography",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified and reproduced with permission from: Chou R, Qaseem A, Owens DK, et al. Diagnostic imaging for low back pain: Advice for high-value health care from the American College of Physicians. Ann Intern Med 2011; 154:181. Copyright &copy; 2011 American College of Physicians.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_27_30141=[""].join("\n");
var outline_f29_27_30141=null;
var title_f29_27_30142="Y system for peritoneal dialysis initial";
var content_f29_27_30142=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F57532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F57532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 591px\">",
"   <div class=\"ttl\">",
"    Y system for peritoneal dialysis (initial design)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 571px; height: 410px; background-image: url(data:image/gif;base64,R0lGODlhOwKaAeYAAP///wAA/oCAgEBAQAAAAMDAwKCgoPDw8NDQ0DAwMODg4GBgYBAQEFBQUCAgIHBwcLCwsP8AAJ+fn5CQkAAAnvDw/wAADwAAzmBgnzAwngAA7gAAL/+goAAAXw8PD+/v7/8gIC8vL19fX8/Pz/+wsP8QEP+AgP/Q0P9AQP9gYP/AwP9wcAAAH98AAAAAPwAAjtDQ//+QkAAA3o+PjwAAf//w8FBQn5CQoL9gYP9QUN/f32BgjzAwX//g4BAQngAAvu9AQG8AAJ9AQKCQkO9gYJ+AgD8/P7+/v4CAn88AAHBwnzAwP+Dg778AAFAQECAgjzAwb49AQN8wML8wMO4gIODg/+/Q0LCgoP8wMM+QkIBwcDAQECAgnwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAA7ApoBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwocSLCgwYMIEypcyLChw4cQI0qcSLGixYsYM2rcyLGjx4+xCigQpGBkJQMGACA4cGhAowKVEDxYdABBJJQgczIkkECQAAGWfgJ4YNMQgUYuKRVIWmipIJmRhOqcChACS0IEBKSUKmDAApZAARhgacAkyQUDBgAtOzQtBEFH/yeYNLAS7VcAQA/Yvfq0gVpBBryOdMpWwVYHAkSmPNBVAMsCENDCJCRgAVqbCtA2KBp4QViqoNc9YGAW7oGeQh8AheByQIEDDFIeJZQApmcArgG8PeBg5FHVAGAfaDBBt82jxI0TYrCyuIEGBwo4AOA0N+HaCpzerox3gAIE0ylDR8AAwHeV0yFAVzA7tPtyCBIkKA0XrwGhDH4KOPrz/mamKvWEF1DWPTAAAzAdpcB0BiwAwAINQGDSURBKWIgDD7wGQAOTDYBAdTA55RR1LpUnSHlStedTWLk1OABybwGg4ns0emNAfogcdZpQBBTgY4gNQDfAfYSMKJRrECRgU/9uszVggJKALYCgjFFOOcgBEzTAwAG54eZjayG6NKJT7fEX1oxSufbAAr55WV+NcG6jl5WHzCYAYrgVp5IgCTg4QW2ECDcUgQUIMNNpCQoiXVKTAXdUo59Rx2cBExw6nVMRiiWmgJi+VUADA745iFCw4fYWe4MGN2OcrEoD3gB81SkIbHk1IB+oG6aEaiFPBknoaQPYmqggDsQoQAJpscQfsrASYmsChy4gn6diOuBVUmkZ4BQCaXkYKpWUWZvAW68+oGNa5raqrjQTEKBnLQsuc1W869YrbwMOFGXLAikp8yqU9gYsTAFFFcAAdAInrPAk5KEW28IQR0xTAgQQ4AD/wBJn3CpOjDRQccX9aixyjQYQYIENi+z3MQGkjexyaAZY8MMFFmCQSMkrE7DZyzznFPMFAQRA8w6HkPexA3L1rLRHPwcdNM0OBupAxQtMtvTVGjXtdNAybBC1IAMkMBbWZGckgAVAb+20Bl6TpG/ZcFO0ANpqq812s3HnPdHcade9tQYuJBCr3oQrtMAGGviteAeCE37AfUkr5eMlP4oEFSMAZgIVx45cXvgihyeu+OLz6Z1AYhNcmnkj+0U6SVY/fdnIqpS7JJUjI36eSOij994Bc3HnDhZiMLG2s2FdhTwI7ZGoSNhIhgW3l4ysfT3r9AKw9oBeuWUWrE1O3Q5A/+R0acomiWJBr+t9QyIQpEld3dUz7733/gLwZcOW4VVPiqTeAQuKTr548zZwWaJHkwMR+pIDgeOkxEnOKk4DZfTABnxnOucBD/rEtwA9keY5AkSfdar1GsRgyUHAYQ3PuIS4+rmQAvgjmwK6wgAHjagBnrmT7L61PEzADigK1E6EJrQiQlSIiN+ajYseZbtIabBBG+rQh8CEvhGNEAD5+QnzIHaaFrrwhQ/LmwN2OIAJ/Cg6SRGfASvhPCqOqEFTspPr4DisFA3lfEzkIdg+BZMuuSaIYsJWmGRUOZedxgWi+2L9KEAA5SntQ7PqTQEEJABcAXBEGBMVG4vkkkwFRv9SqZJjkQThqCJSaQCnyqMaAxOeSgVHdRt6yyetOMgyPmVkp+mAIr8IQ6tdTQH4CluMsjUUZM3HYGFz3YtW1zxOUsdaaMELs5RlSp9ME1x2LJcqXYfFfullWlWEZiD3iL7h3EpkudwlGAuou6Yws53lSKc6ewdDdsJzELm7pznkOU/F1VOfAIUHeXTZT8Xdz54BTSh8GEDQgtbtdwhVKCrcByCKQuKdhCCKSgYHNkbU5CSONERJ4EQeGjjUbxCVKCwGSAiWPmKLg8iNRo3CCM9JQo2m5Jx7yEOBkz60dCpNxac4RJ2shKwARvURTii6m+kRoHqGGOoY0+e9ncmIMaP/qolfgBI9irqONagMTmPAApSwTC4tAsgOTLzXLwOox4Id4alP1cY4jgZ1FAsqSW/YQ7BB8BUBAmDAA8oyHy59SoIOzBUhFFBYQLkmg+E5CqAmicXmoI85WCIEeACYku04iEdFtMxrhDLG4aRkANubgPUwIte5Oq2ud03FBMIigOKsSpTjU0tjjvgm8bnSTS1Cy2yOAkV+AQBDGnIKcmOlAAaY8USDQBFQRMkVAXBLUaC6okYM1lPXBg22sUVFddfYW9pWzUcjoSM2I5WmPhZgTW0CF3NMhCUtoTE4WdrSYo/lkjKFirq0TQyj3IjRiJSsu67VAHjDe4r4gO04NP2W/3SuAslQVlM3SXHsUlLZWzyBsjYimpRfR3IAGFEHVPhhyXZmEir91tZN+bQIEuiW4A00jsGpONbpNFneQTxJmPxtFm4H8YA+aVibb2LPVZ41E0zJh8UkMWZKuJUWmwgldcHiKrIAuxr53EW7GIGBD2h8UrbdGMfkgKI+xUzmfrJNfmgmR28CCoMnWEAGBX1znPfcjQrwwIu71DOfB60NPwPahYIm9Cl8SQmbIoLRhtBpeBdAgEOPrmurVTQp3glTd2IuZdxU6WkSwIQluMCFUNN0js3DvuIgVSsnJmqguuIXVheqLWHFC6u78i6fWMZbVeWMV0INN/JEjTcN9VuqVf+NikeVdq89QkBe85rRtYjpYKt5ZZukU8LSVLIm5YGsbtbT6aWVLGQTYEACkr21oTE7FXl002xm65Ne61dETHnvgRJFS8qwCCZLjCWP4SYlqy0AQ39it9Bq9m54o0/ephTfbPAtiCQtid+C9Pce4XvKyZT7ZVwC6qjbVRYGvKDdDG94sx/OJJY4GDdvA5QKjXQoQMW7S0UsVVhRBZwS5w088gP6uZ/CgO7SzGYqX3m/jzUTHbsuPjgcZ3CQJSwq9XtU4iKXtdLFJdR+XGQ3ehcEnDv0QfD0BylP+j5JEh6yjcZq6baKA0JqNKSr3Rz/iuhFOMCBUoTcLAe38jtRUoH/uxt+EyAAASmAfpVRs4Q99Dm85DnBgQhEQAWiuNFngB5TYk/+85YAgeVREIrAxkg3zh0EBBxgV9Ar7Yw00fsqKm/5CJzAE+bUV9yr7fq4wS5fUU2Kox9dYE6IvvYp6ATU+RL4QuC090qbDWuCjRfiRa87d4GMZKqfGEwUSj/g/wkOal/7IoT//OhP/09wNCv5cPT50OeZEi1okydixykptJ137C8S76tfAC1AfpY3Bf9XgOf3AKfHeYcAf/HnMlnxAMAXcGNSIvphJvURY59AewJYAjXgCWGXCAzYgCKDQKSERw9HJoVkRxjoCccngBFgAh6YeogQgiKYMSqyc4/C/ymtoSdWdibUISD+h37j54KWBwIGeISGkoA1NIOeV4M2qFlbNxvZ4hTmlAAo5oO4MSRBeH4BSISWJwRIaIBhNHV4w3tOeIaFoIHkhwIokAMm0Heas4SzYiv0MXYs8VFo6IQksAIcoAIqcAWyZwmngTCkFEOCECS4cWZ5eIbAEQrmxBdlNysHUzFAuIhOiCykICX6YjCRgjNUY4lOyB5fdwk3koAO8DUvsjJN6AqVE4iSIGmQkDyisBKfMHygyAs4c3qiMHYh43gGkzONdAs/FFKLgHNMSAnPERyiMFOdsIK3qAuURgBQNgrGZkTAFxk544oORwhuFSSMYUt4oT3mcf+K1tUvCtBrlXEZ5qEZwnYbhIBWMxSPbKUokeEhULVY7NMvaZVWbDFUk7GPpWE8NjEBRUGQ2DdFvEZKbuET9/iNg1Vx3/OMpDA1PHEKg8gXgTUZj+MxLGMWsKgKw4gbqVUbvOEbb0Ecp2FGgmIo4gFu5lF/6UFuhSBaJaYWC/IaENQV3/EwEIRPAwR8BGCTj7VXcxaUaaV668F65MEYoLImKgEB3FaSuqFtFKRYwPFJ/xNAEhkKCLAykeeItgKJwXglf9I4OEOMo2AVy/MjF8dyw6JAD5ISczYq/yYWwiVw5GVHKsEoV9hj+JRG0xVTlEJbtmUIOPQTU/UkjaNfipL/cfoWR0V0b52UQ1O1lZ/QLh+DlqGgiWYnWCKFACUjAUfgAZr5CaNhFjOiXUzSmG6CHurhfP/GcUfRJWiChROYRBdmJIG5R+O1KmUEeyWGhazpJRYHcf/Fmr/pI61nmZfAkZ+YCqXoV1Y4OKEpCCNAmqUQH0DFY6o5LA9QHLmGG5VJl8FRHjiYKj6ncQbkYsWhl+KDSRC2Ry/nLatSSbMyEuMyLrjRL1PEmzVXR0Ahc7ZjSV/JnJfAACvTdqjAi1cSNmIpAYRwnaWZCZpnFN0yE90pI2FzF0mSFE9iCHciTOjhdcGBLrUpKknSJ2Tll4rCAMkkKrnhdANXTGGTGTMB/x4IQGWoREvAUnWiBHW1RqPbaaCcQIPUKIeCwJnVWQgSCgpzAmnNtDsTegjzoqCc4Iy1wD+ZRqSfYKSjcJGDkG7mAqGHcJ29pgmvspwvlQj0Egl5BwpYSgsGYC1lyKWlt4p+F5aDQGlkigjXuaWV0C5naqcv46WloKQE0KeJ8KeZMBzAR6hLY6ilcCNj6gg6EAKAugh9RR0Ho6aQmjGSeqiJCgkfgKluqm54MYafqjShOgpLSqqm6ginUTEXo42rCjGtGgqvGgmlmqmF4JxjeauRiqeTOqqV0KueqjIf0zLCyqrE6qrGagmlqoi8AoxW1aw8k6seGK3SGgLUSnRHE/852Noz2rqtinqsIkCtvEE1UDquLlOu5qoJ6RorYTM27oo18BqvmTCvbnOvcJOv+ooJ/OqvcQOwAXsJ6VqgBJutz4oKu2oJImCIC+ust/CwlRCxtjqxCmOwoGCxlDADEquxI8OxHcutliABISuyoNqwq+Cxk4CyGauy6kKyumqylQCzMisyNFuz53qzdJKzuMqyreCykiABwQq0Gyu0Q2uzL6uqSCswI+ULROsIOPu00De1iwCyMWu1zIa1iICxXCuCXlsICRu29nKOWsESzAgMYysIA2u26pIk2mKfxsi2TFsIH2AE3wq3cMKsyihTCxmOqMU9a5WPsDC1pVqnfBv/J5RVCLmxG0VZQRf0TCvxqK7gsr26uPWCgQWyb+t1gYAZCxZ7qb6que7RXIaAJFCymripm7Kwq4xquvXyF8FxWoXyn59rdRm2tTxrnR4wqLIbJ9+UFuD5GlRnc6b0KC66Y3KaqE0avMFTfJdLANgJvdGrCx9pvdq7vdzbvdRgi48gvd7LYHHKCKM4vgkVP/35jY6hElsFkVbVGeeLvvrklAgAlS7hWZWVWVnJelk5v/QLT4x5WdF1XPuzIZT5KTECwAGsO21kQDqSX1xiRspJmw2MZlqoEp1yYh9WKATacwx8wYSjo/i7l1W2IU9GSsakAF23HyL8wjCcdNkbw2p3/5Y0HCe6OAwHxkhTesNx5bR221087MPvQR7T+AsHtjVDTMShER+lawtJrDZLzMRUASyeOgtRXDdTTMU68Yi4SAAI5jdbzMU5wZm5kMWjM8Zk/BHpxrvFGsb0dLRr/BGRiMVgrE5qPMccYTDAu7RwzEtyrMccUY2ie8cFlceCnBGnAWesgMb9hMiJfBGO58euBcmRbBHS4sakaMhzxUh2d8kcMRqajIyc7FOeDACFB8odEZ2m4MgOdcqqDBI30sOY4MqHTACfHMseYcTQ+se3nMu6vMt9UrO+/Mi4HMxVjCxX/IqlfFKwjMxT4cWbYMvGDMzQXMYpOwnUPE/PfM2g0f/GtdzMr3zM3vwedczMxczN5FzO78HHpJzOeLzO7FzESPoI2xzP1jzPoLHIywwY4vzL+swqk6xrinDPitTNAQ0nmUxpORxp/7xLCJ3QcGIuFTPAiGDQaSzPEh0nnqgzjIDRWqzRG10jEACMDe3Q8BzS+TzS7sEYCLqsnppuD63SLF0vLv0xuIIImojREV3TAh1YFZPDHEACA33PPe3TreLSA1x5UqCiYYqgxXzUSK0ujMFiGqgFRsQcrizVAfU4taWwjPAjGqwhkfAjYH0ltrq2jbBUdiW+L6OGJNB+N4bGXB1Qp0MpsBQVWSEWp3jWdfITfuGp4EuerfkIqWFPDBz/wlShhhGQfE4cK1Fc1wAlPNxXPBGJPBmMFYL5Oj7mEoZRKNQXPdpXt/BYRu8DvwXkPX/BFgaSa3ExF3XhFWq7kK82ZX5x0jTC2BFQApx4CDss0kGlP2TdPwrQvwJUuQXUHnXrCCqSLwbTAGkFkxu0f1ZKk4OrWuMGQKxHG7ZBKFMplb+RF1vCQDYBuSURbYzFwsv9HrpteU6gmTiz0io1QwdiQ0lxmDrkuppNTpJwgztkly+yQcJpSleE3+P5ckcSIgYCmfFSXEOkKAs+LBOgW7QLJ+1teSuwCAYg3+E1RlZEwa+h3z3E31FKLPd1R9vWRDzWXiIE4nzhuqrblk3y/yScUXDFybqVYdZxcuFF2AipjGMVVpKNa5/BkR27WwjK3a6L0B4L0GTYwmHhM+B4wWJXROQAdCX6BRyuwZKIAi6Loiik9BO4SwCPsd17AidRkAReaHm3l3TAlHVgo4VFVqPIxLwxFZRDoW5bG5Qv+nBIFuU8xlgeol1zPqS9At1e0qPISyzGMk2KDhNMJxbGhNtdnMknkAJeGANoWL7b0Ka45H6DMARB0IKWhwWb7tbYYFzVAHuKgIfXQMiFaBMkkAPk1wNTjQ2/x04jMtjOpAnfF4bAfoQyGBy28jY9sAIlEAFweOvVIH3ewY6VfX3x8xj1COnEkwm/Huzajn4IeP8lyowIHACDOWtRm4DqkECLnKDWwggY9Iceki4S+Lca+je5xL0MsL64LnVAI94JGqXYqavks/CAEXiXt5lFLqyC5t4L1iK7ta1UKdEZ6pM87gNX+GRU1OMV11PhJGG47ptrAFkWtR1r/9iQaBEWgUG7610LJIjiusuaCDQ5CN8Mj625fxVYgwVC0vFMJeQY2O1X0VaVEAQojagoPylthcUkQikS6E2UvvFAKSH0QMQSEJTytHCDUK6DeXJLKliJlpDt2/71+tHts+KgmotbsuYh/RZj/jUg4PET0fSXKzLhP/EXSQ4u9IYXhcn2iFEZnt0VeEL1AQ+FJJqF2uISVdj/l+BCTJQD9owPfuyXpJZrtrjlR2Q0SPu9XpPElr2uH+fVf3WPW6A1IJnvI9JWLKEC+IM8nU8N8DKLW67EG275cMtzFXIEG0XxNvA5Ybf0+S4nIPS5Irb/FI17G6jPEX/nY0CMtLj1TfqZ9pkT6T9qTJFS5yY/6QYUo9AiTcwb/S8qLVlW2KHxdp35xHPM6YXzgVFGiLFs/oXDeGO/t8zeMwP9INkc/zxjxuPDAJTuY7QMCACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXhQWYm5ydnp+goaIABgQGgwYMp4mlpqOvsLGys7S1ggMABbi2vL2+v7AIDAuDwsSHpRISrsDN/87P0MENAxOkAwMCAAirCtXZAg4CBRMKggYI0enq668HCQkHggoJDfGEyYLLq+z8/f7AChwgOFCtQLwGBhQwEDSBGAFSCQooeJDtAAN7/zJq3AjgwAKBgg4MgIeKgARC+jiqXMny0YQHhBQIGBAOAEIADso91CXPAaljLYMK5TVB1aAFDNDhK5RyqNOn/gRk6wkBgNRcAxDs2rnLpoEE6KCKHcupAAOY5s6aRNSUrNu3swr41FYggaAFUx0MWLXTriC5XeEKHoxo3gB7C9Ymaku4seNJAhIMaABggeQGUyfMBfAQwLVVDqo+Hi34QAOwSxUxJs26NaeArmOLFcBAMf+j1bJz6060YN/u3xpTN8INvLjx48ibCXdEPLnz59CjT1r+qLn069izJ6cOybr27+DDN+Yeybv48+jTryRfnpn69/Dj92Pf3b38+/jz16Jf3b7+/wAGeAl/zPkn4IEIJmgIgcMZqOCDEOrH4G0ORmjhhehNuIh5GHbo4XMaqlbhhySWWFyIi41o4oossoYiWyq2KOOMb714CIc05qhjSzYaguOOQAY5n22W/CjkkUgqR2QlRibp5JOy9IhSjFBWaeUoUgLQ5JVcdllJj1t6KeaYjbwYJplopllIiGeq6WaaE7b55pxjEignnXh2Sd+defZpJXl8+inok9QFOuihSAr/ZyiijAa51KKNRqpjMpBKaumMrfh26aZ1asrpp6CGKuqopJZq6qmopqrqqqy26uqrsMYq66y01mrrrbjmquuuvPbq66/ABivsJweUM+yxxVUARVLINptbBRlYQAOzzlY7GrQWXBBABw5gZO23b2GrbQDbkgTuuWKJS+66HZiL7rstqbsuu+7Ca29G8s677gaB3evvOvnqS64GGwD178HPBCzwwAUj7DAwCi/MsMEPVxxLxBIPzALFFncMig3ZZpzxBRZ46vHJl2AQssgjl4zyyymvzHLLN1QB882QLCDzzC2bjPPPhOg8Ls8iU0CAEkAnbYjQRLNsdAYVKC11ZTs3/y3w01FPnTTTVkuMtdZbV931ul+D/fMCLAw99rxlm33zAhtosPbVBEDtNs5wyz0323VnfffLee/Nt91/Ax634GT3XbjheiPe9uIdB454AI9DXrHkjitueccPsNC44JVv7nApFEweuuijE1D63qejnvrqY7fu+uuxaz47yqRbLfvtDgujOtG7836wMALk7rTtwndcyirGe4188hWnoglDtcGub/DQ24tUWJUJ1HzihGf/sEcJGOuOud9jL/6559uDgAMUG6/++t8ikABQEDBQzYKqz09/tcJAi1UYIJpD3IAAz/ufvVKxCo+AJBEVMAAX/KbAe6VCNO1zBAUr+K7tCf/CGBy8GfmMlYr9hRBlGRxgAU/oMfsdw4Hce9cBDCAAclSiADiki0EUgENjLYKHEkHETHzWCARMAxL9+g0ODbKIA8TQMQEMiWS89a4EiEMzWJGEAAiQDQPAj4fXmN4idDEAMd6DMlSEhEDSqIjOGIeL4HhiFrUhQEXwZBMFkIoe98jHPvrxj4CUilG0MYx/3bEjVgmHJiAwGXQogIZ7MYQbyyiIqzjCkgaAQAMaUI5riIN55TAiNio5gAV4qwBcNAAODXAKRjYAHR4pZTwIwEiOyaYzjFTAAhqZSHE8kpSmzAUEdqkJcIgDE3kMpDKXqcwHMG+Q/rLIA5gIEYloslj/3ZLLQB44iElOz5KNsOQAHkAQYixgAQVg5C00kRSCAIAiAFDnIBRAgAIggDbOvGZATFMNCKDDFTf5TWcMwEl0vK+aYHxnNtQ5EwUc9CtBfMoBCFBHf8lkAIW8YwPwAg4c7gKcgvBmJacSzqlQkidXuSMlHTDNeDBAj24M6UgFsVGpOKAAC2gABIzVGZDmhosPAIkBdsmVv+DipVJ5iCWLOpYSWuymKp3AEg9wR5+K1CokZYQ4NYHSbKhUEwRpwEXqucRC9NSkUsVhPIbKAE2cFThkFcQDFqCTOfKErDlc6hyRycy++lWPDyggCP2FgOkdICd1qSRlOpJQAIDFrIOg/yRWH7HVLF7Ffh2JSC4EERFqfBCyk7XKYos1PXi+VaCEGEBV6JkLv/DEs9oIbV/K8tfaMvOlg3DHYe6lgAboJQGi+cw7JVM+s4wkq54hAC4ewADUOMABRLzHc09xUlxY8jSn0cRpEgAT07xjsd2cqVyJKxPJ7Pa0u4np+8bZmc/wxLv0kO0tIjkU+9UjJJaRo8cOuT6RlG8QtDHjyfhLP+aKcXmFOEEMYsDChzn1g2dRgQlQUIIIRIADDX7Y+xZgBRKsgAoWDnEEQFBgg7IxiYZw4peiCwAF+JBTHABCC0RM4wiYgH6UfIB+Y4oIBFQUEj41qjlYjCgO1JjGJaiBIv9YCbkCbPKmpCjHA64hmofYkBQD2aUpfylK5DJStR2ZiQDicZWp5FWROdQlfdNJzCIfOcREWDICifyzeSjAHZqgZFUOW1d4WoSf8SzsUQdiQm1065d4sQoxrvJWiMokGzc1zSkaelA3v3kLyC2JMqiEs5es0zNcnXJbOdNinwy1MjotB09YSk156G96CxHEQhg906oKQCt/oYxeGWXkGqfAhVR8FKdhVtkyQuCxlOwMQh77k7a+dwJi9VZ5ceFGpWbjrba+Y1dl2qhei/gEmXWXooaNMnlqtowC6K5mOwOYv8hVHLiYnmblUY6J2qQqTp7sRSrjVb9cZd81lG+kvB3/gSbsw4OFIvfJHnC/cxvkMuseRGgqaV6q4mK7dTRMAk6hlWug4yqamYxJ93KVY9+PzFPhsaUjkIWzDKIoD1jSICp1M9gskBBGJrFhECPzKdG5cL3RXkU5QIKQnGYbPWeKwjMsK5EQQL+EoE3SfbR0prvKHQTYDCumfqOqH0zAlGAysaB+KawTwJb34DqMfv4wFJN6EZYMMiZ8HFpOzQOBtJTzSSZBc2dl45EzKUgqc7FJAXtSJnOVrCufmMlN2mMmwVxlQqiLjTuLOR5slqwo8f1Nc2iyHoF3ku8QGGtEZKnvyNpJpHNCT3sGxMU5CRo6D0Bpn+izW6mFCbQVGk/r/55Flbg4p0ESLYBFD8ChPrGzSJLJ7XESJCJ8RtLoEQhe/u29SF6HF1OTzZCpBBzA3k+5TTgK5chO7yFI3WJotw2A0s9a/BPAhph3Xd1PHyl/eB9RlmaefXRt363iBVJxJ37UMFWpdX6csUTFZGbWJX4ypVfFt0SP1nxctQuSdSRmRwBspGmbgHrB8n+cEQ+Y5RkxlG7ipVSj9WJ6Rhmw9XEMaBVooVOEJ19y4T6exlqgNkcXKCRm8RV+oXcd2H/fAoKRARORYUWFYBj35IAMNxIqaF6wtF269oJK2HFZIXBfMRIQcFjs9WlflSRI2GJlonYFwnbCs4OtEhmSsH/5IP+EloOGq6IQYDeG14d9Zmh1nDJOX0KGDXKHeCgp+bOBjsCGWuKGf9gnFrFCYceHFOKHhzgoU8YJhOiBj9glZvFiA8KIG2KIlZgmYdgJk8iJnSgmaggKoeiIo4gmcigKp5iKkaKHWKKJKYKKrtglgQgLpyeKtegkiRglsuhzu4gokTgLZqKLwZgf3VA88aBjnXCJ+yGLlHiM6nFsqiQALDiHlPCJtBAnxiiN98EAPhQPOUZllcRI5NRmgEdfAPaDtmAn3eiN8ZFYhaBnHRF7AFVQPqFNh8U9q+gLe/KO8AgfBJaDBSBqAEiDH0VSsPgLgAKQAfkeCmEIxoZsB6lXtib/CLeoJHXYhrT4kAIySh1BXXmkbhUpfnfEbMUCDePWkR4ZIORzDdVQRrqVXW9nkQxwXPwgbCzZkjkykOtAKQ7JkyTikz85Z0L5LWJ3lEq5lC1Bd5XgdkyJKkTpCCoXlaUCeYIWZtgggtMwFYtnDqVUlVYpKnOlDRDAE8RHDO3UT/WwT/oklmMJKvsmZO6HEy01fjblZFUWl6cSU3cVXmF1EQWoVpIFl3y5KfSVlTKYb/KWRynoZ4Z5mJZihWeJC1aIDhg3Xk4oEtgQmZL5maAZmqI5mqRZmqZ5mqiZmqq5mqzZmq75mrAZm7I5m7RZm7Z5m7iZm7q5m7zZm775m8AZB5zCOZywEAgAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With the initial Y systems, the patient connected the bag with the fresh dialysis solution to the other arm, and the base of the Y to the Tenckhoff catheter. The first step after spike was to flush out microbes that contaminated the spike by draining a small volume of fresh dialysis solution into the drain bag. The peritoneal cavity is then drained (step II) before the new dialysis solution is instilled (step III). This \"flush before fill\" sequence, in contrast to the standard spike, flushes any possible contamination of the spike away from the peritoneal cavity into the drain bag.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_27_30142=[""].join("\n");
var outline_f29_27_30142=null;
var title_f29_27_30143="Gravitational changes on HRCT";
var content_f29_27_30143=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal HRCT of lung with positional changes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 319px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    HRCT of lung with normal gravitational changes that lead to an increase in density in the posterobasal and laterobasal segment of the lower lobes (arrows). A repeat prone scan would clearly demonstrate the transient, positional nature of this opacity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_27_30143=[""].join("\n");
var outline_f29_27_30143=null;
